Aurinia Pharmaceuticals (AUPH) 10-K 28 Feb 23 2022 FY Annual report Financial data

Cover Page

Cover Page - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Feb. 27, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-36421
Entity Registrant Name	Aurinia Pharmaceuticals Inc.
Entity Incorporation, State or Country Code	Z4
Entity Address, Address Line One	#1203-4464 Markham Street
Entity Tax Identification Number	98-1231763
Entity Address, City or Town	Victoria
Entity Address, State or Province	BC
Entity Address, Postal Zip Code	V8Z 7X8
City Area Code	(250)
Local Phone Number	708-4272
Title of 12(b) Security	Common shares, no par value
Trading Symbol	AUPH
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Entity Shell Company	false
Entity Public Float			$ 1,420
Entity Common Stock, Shares Outstanding		142,576,689
Documents Incorporated by Reference	Portions of the registrant’s definitive proxy statement to be filed with the U.S. Securities and Exchange Commission pursuant to Regulation 14A within 120 days after registrant’s fiscal year end of December 31, 2022 are incorporated by reference into Part III of this Annual Report on Form 10-K.
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Central Index Key	0001600620

Audit Information

Audit Information	12 Months Ended
	Dec. 31, 2022
Auditor [Abstract]
Auditor Name	PricewaterhouseCoopers LLP
Auditor Location	Oakville, Canada
Auditor Firm ID	271

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash, cash equivalents and restricted cash	$ 94,172	$ 231,900
Short-term investments	295,218	234,178
Accounts receivable, net	13,483	15,414
Inventories, net	24,752	19,326
Prepaid expenses	13,580	11,710
Other current assets	1,334	796
Total current assets	442,539	513,324
Non-current assets:
Other non-current assets	13,339	11,838
Property and equipment, net	3,650	4,418
Acquired intellectual property and other intangible assets, net	6,425	8,404
Right-of-use assets, net	4,907	5,383
Total assets	470,860	543,367
Current liabilities:
Accounts payable and accrued liabilities	39,990	34,947
Deferred revenue	3,148	190
Other current liabilities	2,033	4,450
Operating lease liabilities	936	1,059
Total current liabilities	46,107	40,646
Non-current liabilities:
Deferred compensation and other non-current liabilities	12,166	15,950
Operating lease liabilities	7,152	7,680
Total liabilities	65,425	64,276
Commitments and Contingencies (Note 13)
Shareholders’ Equity:
Common shares - no par value, unlimited shares authorized, 142,268 and 141,600 shares issued and outstanding at December 31, 2022 and 2021, respectively	1,185,309	1,177,051
Additional paid-in capital	85,489	59,014
Accumulated other comprehensive loss	(1,061)	(852)
Accumulated deficit	(864,302)	(756,122)
Total shareholders' equity	405,435	479,091
Total liabilities and shareholders' equity	$ 470,860	$ 543,367

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value ($ per share)	$ 0	$ 0
Common stock, issued (in shares)	142,268,000	141,600,000
Common stock, outstanding (in shares)	142,268,000	141,600,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue, net	$ 134,030	$ 45,605	$ 50,118
Operating expenses:
Cost of sales	5,664	1,091	0
Selling, general and administrative	196,371	173,536	97,272
Research and development	44,988	51,139	50,327
Other (income) expense, net	(1,523)	574	6,809
Total cost of sales and operating expenses	245,500	226,340	154,408
Loss from operations	(111,470)	(180,735)	(104,290)
Interest income	5,118	529	1,516
Net loss before income taxes	(106,352)	(180,206)	(102,774)
Income tax expense	1,828	760	(94)
Net loss	(108,180)	(180,966)	(102,680)
Other comprehensive loss:
Unrealized loss on available-for-sale securities, net of tax of nil	(209)	(47)	0
Comprehensive loss	$ (108,389)	$ (181,013)	$ (102,680)
Basic loss per common share (in dollars per share)	$ (0.76)	$ (1.40)	$ (0.87)
Diluted loss per common share (in dollars per share)	$ (0.76)	$ (1.40)	$ (0.87)
Weighted-average common shares outstanding used in computation of basic loss per share (in shares)	141,915	129,369	118,473
Weighted-average common shares outstanding used in computation diluted loss per share (in shares)	141,915	129,369	118,473
Product revenue, net
Revenue:
Total revenue, net	$ 103,468	$ 45,488	$ 0
License and collaboration revenue
Revenue:
Total revenue, net	$ 30,562	$ 117	$ 50,118

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Shares	Additional Paid-In Capital	Accumulated other comprehensive loss	Accumulated Deficit
Balance (in shares) at Dec. 31, 2019		111,798,000
Balance at Dec. 31, 2019	$ 298,600	$ 746,487	$ 25,394	$ (805)	$ (472,476)
Increase (Decrease) in Stockholders' Equity
Issuance of common shares upon public offerings, net of issuance costs (in shares)		13,333,000
Issuance of common shares upon public offerings, net of issuance costs	187,732	$ 187,732
Exercise of warrants (in shares)		1,000
Exercise of warrants	1	$ 2	(1)
Exercise of stock options (in shares)		1,593,000
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units	6,643	$ 10,107	(3,464)
Share-based compensation	17,454		17,454
Net loss	$ (102,680)				(102,680)
Balance (in shares) at Dec. 31, 2020	126,700,000	126,725,000
Balance at Dec. 31, 2020	$ 407,750	$ 944,328	39,383	(805)	(575,156)
Increase (Decrease) in Stockholders' Equity
Issuance of common shares upon public offerings, net of issuance costs (in shares)		10,166,000
Issuance of common shares upon public offerings, net of issuance costs	196,740	$ 196,740
Exercise of warrants (in shares)		1,434,000
Exercise of warrants	365	$ 2,102	(1,737)
Exercise of stock options (in shares)		3,238,000
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units	23,421	$ 33,073	(9,652)
Issuance of common shares in conjunction with ESPP program (in shares)		37,000
Issuance of common shares in conjunction with ESPP program	585	$ 808	(223)
Share-based compensation	31,243		31,243
Unrealized loss on available-for-sale securities, net	(47)			(47)
Net loss	$ (180,966)				(180,966)
Balance (in shares) at Dec. 31, 2021	141,600,000	141,600,000
Balance at Dec. 31, 2021	$ 479,091	$ 1,177,051	59,014	(852)	(756,122)
Increase (Decrease) in Stockholders' Equity
Exercise of stock options (in shares)	77,000	383,000
Shares issued on exercise of stock options and vesting of performance awards and restricted stock units	$ 521	$ 5,064	(4,543)
Issuance of common shares in conjunction with ESPP program (in shares)		285,000
Issuance of common shares in conjunction with ESPP program	1,912	$ 3,194	(1,282)
Share-based compensation	32,300		32,300
Unrealized loss on available-for-sale securities, net	(209)			(209)
Net loss	$ (108,180)				(108,180)
Balance (in shares) at Dec. 31, 2022	142,268,000	142,268,000
Balance at Dec. 31, 2022	$ 405,435	$ 1,185,309	$ 85,489	$ (1,061)	$ (864,302)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)
Cash flows from operating activities:
Net loss	$ (108,180)	$ (180,966)	$ (102,680)
Adjustments to reconcile consolidated net loss to net cash used in operating activities:
Depreciation and amortization	2,706	2,761	1,371
Upfront license and milestone expense	0	10,000	0
Share-based compensation	32,300	31,243	17,454
Write-down of inventory	3,646	245	0
Other, net	(3,184)	658	9,477
Net changes in operating assets and liabilities:
Accounts receivable, net	1,927	(15,415)	(650)
Inventories, net	(9,072)	(5,644)	(13,927)
Prepaid expenses and other current assets	(2,404)	(5,335)	2,559
Non-current assets	(839)	247	0
Right of use assets	476	106	(5,489)
Accounts payable and accrued liabilities	699	4,076	13,620
Deferred revenue	3,048	0	0
Lease liabilities	(652)	332	8,407
Net cash used in operating activities	(79,529)	(157,692)	(69,858)
Cash flows from investing activities:
Proceeds from investments	464,316	354,427	52,108
Purchase of investments	(523,993)	(438,958)	(202,951)
Upfront lease payment	(663)	(11,838)	0
Upfront license payment	0	(6,000)	0
Purchase of long-lived assets and intangibles	(292)	(303)	(5,668)
Additions to internal use-software implementation costs	0	(1,198)	(1,675)
Capitalized patent costs	0	0	0
Net cash used in investing activities	(60,632)	(103,870)	(158,186)
Cash flows from financing activities:
Proceeds from issuance of common shares pursuant to Public Offering, net of issuance costs	0	196,740	187,732
Proceeds from exercise of stock options and employee share purchase plan	2,433	24,007	6,642
Proceeds from exercise of warrants	0	365	1
Net cash provided by financing activities	2,433	221,112	194,375
Net (decrease) increase in cash and cash equivalents during the year	(137,728)	(40,450)	(33,669)
Cash and cash equivalents, beginning of the year	231,900	272,350	306,019
Cash, cash equivalents and restricted cash, end of the year	94,172	231,900	272,350
Supplemental cash flow information:
Cash received for interest	2,344	749	1,884
Cash paid for taxes	(1,979)	(257)	(261)
Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets
Cash, cash equivalents	94,088	231,643	272,350
Restricted cash	84	257	0
Total cash, cash equivalents and restricted cash	$ 94,172	$ 231,900	$ 272,350

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Description of Business	Organization and Description of Business Aurinia Pharmaceuticals Inc. (Aurinia or the Company) is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by autoimmune, kidney and rare diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first U.S. Food and Drug Administration (FDA) approved oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct pre-clinical, clinical and regulatory activities to support the LUPKYNIS development program as well as our other assets. We engaged with Otsuka Pharmaceutical Co., Ltd. (Otsuka) as a collaboration partner for development and commercialization of LUPKYNIS in the European Union (EU), Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Liechtenstein and Ukraine (collectively, the Otsuka Territories). On August 17, 2021, the Company announced the addition of two novel assets AUR200 and AUR300. AUR200 and AUR300 are currently undergoing pre-clinical development with projected submission of Investigational New Drug Applications (INDs) to the FDA for AUR200 in 2023 and for AUR300 in 2024. On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS to Otsuka. The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland. Aurinia's head office is located at #1203-4464 Markham Street, Victoria, British Columbia, Canada and its registered office is located at #201, 17873-106 A Avenue, Edmonton, Alberta. Aurinia also has a U.S. Commercial office located at 77 Upper Rock Circle, Rockville, Maryland, United States.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of presentation: The Company follows accounting standards established by the Financial Accounting Standards Board (FASB) to ensure consistent reporting of financial condition, results of operations, and cash flows. References to generally accepted accounting principles (GAAP) or U.S. GAAP in these footnotes are to the FASB Accounting Standards Codification (ASC or the Codification). At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under the SEC rules. As a result, beginning January 1, 2021 the Company is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. Certain prior year amounts and notes to the consolidated financial statements have been reclassified to conform with the current year presentation. Other current assets and deferred revenue which were previously included in prepaid expenses and other current liabilities respectively, has been separately presented on the consolidated balance sheets as of December 31, 2022. Inventory reserves which was previously included in other, net on the consolidated statements of cash flows, has been separately presented for the years ended December 31, 2022 and December 31, 2021. Additionally, amortization of intangible assets which was presented separately on the statements of operations, has been included in SG&A and is included with depreciation on the consolidated statements of cash flows. Accounts payable and accrued liabilities and cash, cash equivalents and restricted cash and short-term investments balances have been reclassified in the notes to the consolidated financial statements. These reclassifications have no impact on previous reported total assets, total liabilities, net loss, stockholders’ equity or operating cash flows. Principles of consolidation: These financial statements present the consolidated financial position of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated) as of December 31, 2022 and 2021, and the results of operations and cash flows for the three years ended December 31, 2022, 2021 and 2020. All intercompany accounts and transactions have been eliminated in consolidation. Use of estimates: The preparation of the accompanying financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from those estimates. Segment information: The Company operates in one operating segment engaged in the research, development and commercialization of therapeutic drugs in which revenues are derived from product, license, and contract revenues. Operating segments are defined as components of an enterprise where separate financial information is evaluated regularly by the chief operating decision maker (CODM), the chief executive officer, in deciding how to allocate resources and assessing performance. The Company's CODM allocates resources and assesses performance based upon discrete financial information at the consolidated level. Functional currency: The functional currency for the Company and all of its foreign subsidiaries is determined to be the U.S. dollar, therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the consolidated statement of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date assets were acquired. Monetary income and expense items are translated at the average foreign currency period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations. COVID-19: U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the annual consolidated financial statements and accompanying notes. The annual consolidated financial statements reflect all adjustments of a normal, recurring nature that are, in the opinion of management, necessary for a fair presentation of results for these interim periods. The full extent to which the novel coronavirus (COVID-19) pandemic will directly or indirectly impact the Company’s financial statements related to our estimates and assumptions or results of operations will depend on future developments that are uncertain at this time. As events continue to evolve and additional information becomes available, the Company’s estimates may change materially in future periods. Fair value measurements: The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The Company has determined the carrying values of these financial instruments approximate their fair value because of the relatively short period to maturity of the instruments. Financial assets and liabilities are categorized based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the valuation of the fair value of assets and liabilities and their placement within the fair value hierarchy levels. Concentration of credit risk: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and restricted cash, short term investments and accounts receivable, net. The Company attempts to minimize the risks related to cash and cash equivalents and restricted cash and investments by investing in a range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes. The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as high quality corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Canadian dollar, Swiss Franc and Great British Pound will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses, including commercial and clinical trial costs are also denominated in U.S. dollars, which mitigates the risk of material foreign exchange fluctuations. Major customers : The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the Otsuka Territories. Revenues from the Company's two main customers in the U.S. accounted for approximately 45% and 35%, respectively, of the Company's total revenues for the year ended December 31, 2022. The two main customers accounted for 100% of the Company’s accounts receivable, net balance as of December 31, 2022. Otsuka, the Company's collaboration partner for sales outside the U.S. accounted for approximately 20% of the Company's total revenue for the year ended December 31, 2022. In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. customers, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2023. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to our customers or receivables. Accounts receivable, net: Accounts receivables are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 10). Sales and services that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of December 31, 2022 and December 31, 2021, accounts receivable, net are $13.5 million and $15.4 million, respectively. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company's estimates the allowance for doubtful accounts using the current expected credit loss (CECL) model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. The Company evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for doubtful accounts was nil at December 31, 2022 and December 31, 2021. Accounts receivables are recorded net of estimates of variable consideration for which reserves are established and which result from discounts that are offered within contracts between us and two specialty pharmacies and one specialty distributor in the United States. These reserves are recorded as a reduction of accounts receivable. Cash and cash equivalents: The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of operating accounts, money market funds and bank money market accounts which are recorded at fair value. Cash and cash equivalents totaled $94.2 million as of December 31, 2022. The Company has invested its cash reserves in short term U.S. dollar denominated, fixed rate, highly liquid and highly rated financial instruments such as treasury notes, banker acceptances, bank bonds, and term deposits. Restricted cash : Restricted cash consists of the 2021 Employee Share Purchase Plan (ESPP) deposits of $0.1 million and $0.3 million as of December 31, 2022 and December 31, 2021, respectively. Investments: The Company classifies its debt securities as either held to maturity or available-for-sale in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 320, Investments — Debt Securities . Investments classified as held to maturity are carried at amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized losses reported in other comprehensive loss within shareholders’ equity. Realized losses on available-for-sale securities are recorded in other income (expense), net. Interest income (expense) is recorded separately on the consolidated statements of operations. The cost of securities sold is based on the specific-identification method. Intangible assets: Intangible assets are amortized over their useful lives using methods that correlate to the pattern in which the economic benefits are expected to be realized. All intangible assets are amortized on a straight-line basis. The Company evaluates the estimated remaining useful life of its intangible assets and whether events or changes in circumstances warrant a revision to the remaining period of amortization. The carrying amounts of these assets are periodically reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Refer to the long-lived assets section below for impairment considerations. Acquired intellectual property and patents External patent costs specifically associated with preparing, filing, obtaining and protecting patents are capitalized and amortized straight-line over the shorter of the estimated useful life and the patent life, commencing in the year of the grant of the patent. Other intellectual property expenditures are recorded as R&D expenses on the consolidated statements of operations as incurred. Patents do not contain the option to extend or renew. External legal costs incurred to defend a patent are capitalized when it is believed that the future economic benefit of the patent will be increased and a successful defense is probable. Separately acquired intellectual property is shown at historical cost. The initial recognition of a reacquired right is recognized as an intangible asset measured on the basis of the remaining contractual term of the related contract. If the terms of the contract giving rise to a reacquired right are favorable relative to the terms of current market transactions for the same or similar items, the difference is recognized as a gain or loss in the consolidated statements of operations and comprehensive loss. Purchased intellectual property and reacquired rights are capitalized and amortized on a straight-line basis in the consolidated statements of operations and comprehensive loss over periods ranging from 10 to 20 years. Property, plant and equipment: Property, plant and equipment are recorded at cost and are depreciated using the straight-line method. Expenditures for additions are capitalized and leasehold improvements are amortized over the lesser of the expected lease term or the estimated useful life of the improvement. Expenditures for maintenance and repairs are charged to expense as incurred; however, maintenance and repairs that improve or extend the life of existing assets are capitalized. The carrying amount of assets disposed of and the related accumulated depreciation are eliminated from the accounts in the year of disposal. Gains or losses from property and equipment disposals are recognized in the year of disposal. Recoverability and impairment of long-lived assets: ASC Topic 360 requires long-lived assets, including definite-lived intangible assets, to be evaluated for impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The judgments made related to the expected useful lives of long-lived assets, definitions of lease terms and the Company’s ability to realize undiscounted cash flows in excess of the carrying amounts of these assets are affected by factors such as the ongoing maintenance and improvements of the assets, changes in economic conditions, changes in usage or operating performance and other factors. If indicators are present, assets are grouped to the lowest level for which identifiable cash flows are largely independent of other asset groups and cash flows are estimated for each asset group over the remaining estimated life of each asset group. If the undiscounted cash flows estimated to be generated by the asset group are less than the asset’s carrying amount, impairment is recognized in the amount of excess of the carrying value over the fair value. The Company recorded no asset impairment charges during the years ended December 31, 2022, 2021 and 2020. Leases : The Company assesses all contracts at inception to determine whether a lease exists. The Company’s leases are all classified either as operating or finance leases per ASC 842. The Company leases office space under operating leases that typically provide for the payment of minimum annual rentals and may include scheduled rent increases. The Company also entered into a manufacturing agreement that contained an embedded lease of a dedicated manufacturing facility that will be accounted for as a finance lease once lease commencement begins (see Note 15). The Company made an accounting policy election, the practical expedient that allows lessees to treat the lease and non-lease components of leases as a single lease component. Leases with an initial term of 12 months or less are not recorded on the Company's consolidated balance sheets and to recognize those lease payments on a straight-line basis in its consolidated statements of operations. Fixed costs associated with these arrangements are disclosed in Note 15 of the financial statements. Operating lease ROU assets and lease liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company used the incremental borrowing rate for all of its leases, as the implicit interest rate was not readily determinable. In determining the Company’s incremental borrowing rate of each lease, the Company considered recent rates on secured borrowings, observable risk-free interest rates and credit spreads correlating to the Company's creditworthiness, the impact of collateralization and the term of each of the Company's lease agreements. The lease terms range from 12 to 128 months. Deferred Compensation Arrangements : The Company has recorded deferred compensation arrangements in liabilities for estimated future employee benefits relating to applicable historical employment arrangements. The deferred compensation arrangements are part of the resolution of the board of directors of the company dated March 8, 2012. Pursuant to ASC Topic 710, the Company recognizes future benefits provided by employee retention arrangements, as deferred compensation, which is recognized when the Company determines that it is probable to make future payments. The deferred compensation is based on an income approach for the estimated future net revenues of voclosporin using an internal risk-adjusted net present value of the future payments to be made to the individuals. The Company is required to use judgment to determine the most appropriate model to use to measure the deferred compensation liability and is required to use significant judgment and estimates in determining the inputs into the model. The royalty rates applied to the net revenue are dependent on the type of net revenue earned, which includes product sales and royalty revenue. There are multiple unobservable and inherently uncertain inputs. The determination of this deferred compensation is subject to significant judgments and estimates in determining the assumptions related to future net revenues and the determination of the discount rate for the net present value calculation. The net revenue estimate for the United States includes assumptions related to the number of patients being treated (including patients who initially start taking the product but subsequently discontinue), dosing adjustments, duration of treatment, timing of generics and competitors entering the market, market penetration and potential future use in new indications. Additional variables for ex-U.S. geographies include timing of approval in ex-U.S. territories, escalating royalty rates, net pricing, government payor coverage of the product, and market penetration. In determining the estimate for ex-U.S. revenues, the Company relies on forecasts provided by its collaboration partner. Management developed the model and inputs in conjunction with their internal scientific team and utilized third party scientific studies, information provided by third party consultants engaged by the Company, information from medical and pharmacy claims databases and research papers as sources to develop their inputs; application and usage of these inputs is also informed by product sales and distribution data, ongoing market research fielded by the company and third parties, and our continually evolving understanding of the market as the U.S. launch progresses. Management believes the liability is based on reasonable assumptions; however, these assumptions may be incomplete or inaccurate and unanticipated events and circumstances may occur. There are numerous significant inputs into the model all of which individually or in combination may result in a material change to the obligation. Initially, these obligations are measured at the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting periods. Subsequent re-measurements as a result of performance obligations met by the Company or changes in assumptions are recognized in the consolidated statement of operations. Contingencies: In the normal course of business, the Company may be subject to loss contingencies, such as legal proceedings, amounts arising from contractual arrangements and claims arising out of the Company’s business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies , (ASC 450), the Company records accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. The Company, in accordance with this guidance, does not recognize gain contingencies until realized or realizable. Common Shares: The Company’s shares have no par value and therefore, upon issuance of shares, all amounts related to the shares are credited to common shares on the balance sheet. The value of common shares includes cash amounts received or paid for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs associated with equity offerings. Inventories: Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories mainly include third party manufacturing costs, transportation, storage, insurance and allocated internal labor. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories. Revenue Recognition: Pursuant to Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied. Product Revenues In the United States (and territories), the Company sells LUPKYNIS primarily to a limited number of specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer. Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as addition information becomes available. Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of December 31, 2022, the Company did not have any material adjustments to variable consideration estimates based on actual results. More specifically, these adjustments include the following: Prompt Pay Discounts: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized. Customer Fees: The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as SG&A expense. Government Rebates: The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet. Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. Co-payment Assistance: Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual for co-payment assistance is based on the co-payments administered on the Company's behalf by the specialty pharmacies. Payor Rebates and Administration Fees: Payor rebates and administration fees represent our estimated obligations to third parties, primarily benefit managers. Accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability. These rebates and fees result from formulary position and price increase limit allowances (price protection) and administration fees. The calculation of the accrual for these items are based on the estimated payors buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period. Manufacturing Supply Services: The Company also has agreements with its partners that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. If the Company is entitled to additional payments when the licensee exercises these options, any additional payments are recorded as product sales when the licensee obtains control of the goods, which is typically upon delivery. Certain agreements include terms where the Company can partially bill for drug substance used before the manufacturing cycle is complete, resulting in a deferred revenue which is to

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement	Fair Value Measurement The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The carrying value of accounts receivable, accounts payable and accrued liabilities approximate their fair values because of their short-term nature. Estimated fair values of available-for-sale debt securities are generally based on prices obtained from commercial pricing services. In connection with measuring the fair value of its assets and liabilities, the Company seeks to maximize the use of observable inputs (market data obtained from sources independent from the Company) and to minimize the use of unobservable inputs (the Company’s assumptions about how market participants would price assets and liabilities). As a basis for considering such assumptions, a three-tier fair value hierarchy has been established, which prioritizes the inputs used in measuring fair value as follows: • Level 1 - Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. • Level 2 - Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3 - Unobservable inputs that reflect the reporting entity’s own assumptions. The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis: December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 94,172 $ — $ — $ 94,172 U.S. agency security — 4,948 — 4,948 Corporate bond — 104,080 — 104,080 Commercial paper — 125,187 — 125,187 Treasury bill — 12,282 — 12,282 Treasury bond — 42,220 — 42,220 Yankee bond — 6,501 — 6,501 Total financial assets $ 94,172 $ 295,218 $ — $ 389,390 December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 231,900 $ — $ — $ 231,900 Certificates of deposit — 3,140 — 3,140 Corporate bond — 21,820 — 21,820 Commercial paper — 206,724 — 206,724 Treasury bill — 2,494 — 2,494 Total financial assets $ 231,900 $ 234,178 $ — $ 466,078 The Company's Level 1 instruments include cash, cash equivalents and restricted cash that are valued using quoted market prices. We estimate the fair values of our investments in corporate debt securities, government and government related securities and certificates of deposits by taking into consideration valuations obtained from third-party pricing services. The fair value of our short-term investments classified within Level 2 is based upon observable inputs that may include benchmark yield curves, reported trades, issuer spreads, benchmark securities and reference data including market research publications. At December 31, 2022 and December 31, 2021, we reclassified $125.2 million and $206.7 million of commercial paper from Level 1 to Level 2, respectively. Additionally, at December 31, 2022 and December 31, 2021, the weighted average remaining contractual maturities of our Level 2 investments were approximately for 7 months and 8 months, respectively. It is the Company's intent for these investments to have an overall rating of A-1, or higher, by Moody’s, Standard & Poor’s and Fitch. No credit loss allowance was recorded as of December 31, 2022 and December 31, 2021, as we do not believe the unrealized loss is a result of a credit loss due to the nature of our investments. We also considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not significantly impacted. Refer to Note 4, “Cash, Cash Equivalents and Restricted Cash and Short-Term Investments,” for the carrying amount and related unrealized gains (losses) by type of investment.

Cash, Cash Equivalents and Rest

Cash, Cash Equivalents and Restricted Cash and Short-Term Investments	12 Months Ended
	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Cash, Cash Equivalents and Restricted Cash and Short-Term Investments	Investments As of December 31, 2022 and December 31, 2021, the Company had $389.4 million and $466.1 million, respectively of cash, cash equivalents, restricted cash and short-term investments, summarized below. As of December 31, 2022, $295.5 million were available-for-sale debt securities which are carried at fair market value and nil were held to maturity. As of December 31, 2021, $215.0 million were classified as available-for-sale and $19.2 million were held to maturity which was carried at amortized cost and was approximately equal to fair market value. December 31, 2022 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 94,172 $ — $ — $ 94,172 U.S. agency security 4,951 — (3) 4,948 Corporate bond 104,174 — (94) 104,080 Commercial paper 125,255 — (68) 125,187 Treasury bill 12,290 — (8) 12,282 Treasury bond 42,301 — (81) 42,220 Yankee bond 6,503 — (2) 6,501 Total cash, cash equivalents, restricted cash and short-term investments $ 389,646 $ — $ (256) $ 389,390 December 31, 2021 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 231,900 $ — $ — $ 231,900 Certificates of deposit 3,144 — (4) 3,140 Corporate bond 2,593 — (1) 2,592 Commercial paper 206,764 — (40) 206,724 Treasury bill 2,496 — (2) 2,494 Total $ 446,897 $ — $ (47) $ 446,850 Held-to-maturity securities corporate bond 19,228 19,228 Total cash, cash equivalents, restricted cash and short-term investments $ 466,078 As of December 31, 2022 and December 31, 2021, accrued interest receivable from the investments were $1.1 million and $0.1 million, respectively and recorded as prepaid expenses and other current assets on the consolidated balance sheets. As of December 31, 2022 and December 31, 2021, the Company had $0.3 million and $47 thousand of unrealized losses on available-for-sale securities, net of tax, respectively, which are included as a component of comprehensive loss on the consolidated statement of operations. Currently the Company does not intend to sell the investments before recovery of their amortized cost basis, which may be maturity. We have determined that the gross unrealized losses on our investments at December 31, 2022 were temporary in nature. Realized gains or losses were immaterial for the years ended December 31, 2022 and December 31, 2021. The Company's investments as of December 31, 2022 mature at various dates through September 2023.

Inventories, net

Inventories, net	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Inventories, net	Inventories, net Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories mainly include third party manufacturing costs, transportation, storage, insurance, and allocated internal labor. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories. As of December 31, 2022, we have recorded reserves of finished good inventories of approximately $3.9 million which were primarily related to process validation batches used for FDA approval. Additionally, as of December 31, 2022 and December 31, 2021 we have inventory deposits of $5.5 million and $3.9 million that are primarily related to the purchase of drug substance that are currently recorded under prepaid expenses and other current assets. The components of inventories, net are as follows: (in thousands) December 31, 2022 December 31, 2021 Raw materials $ 2,217 $ 2,217 Work in process 21,059 12,566 Finished goods 1,476 4,543 Total inventories, net $ 24,752 $ 19,326

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Prepaid Expenses	Prepaid Expenses Prepaid expenses are as follows: (in thousands) December 31, 2022 December 31, 2021 Prepaid assets $ 5,451 $ 5,316 Prepaid deposits 6,330 4,762 Prepaid insurance 1,799 1,632 Total prepaid expenses $ 13,580 $ 11,710

Property and Equipment, net

Property and Equipment, net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, net	Property and Equipment, net Property and equipment, net are as follows: (in thousands) Estimated Useful Life December 31, 2022 December 31, 2021 Construction in progress — $ 255 $ 393 Leasehold improvements Shorter of term of the lease or estimated useful life 2,978 2,978 Office equipment 5 645 645 Furniture 7 976 976 Computer equipment 3 251 262 5,105 5,254 Less accumulated depreciation (1,455) (836) Property and equipment, net $ 3,650 $ 4,418 Depreciation expense for the years ended December 31, 2022, 2021 and 2020 was $629 thousand, $663 thousand and $82 thousand, respectively, which is included in SG&A expenses on the consolidated statements of operations.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. December 31, 2022 (in thousands) Weighted Average Gross Carrying Accumulated Net Carrying Patents 12 $ 1,569 $ (1,262) $ 307 Acquired intellectual property and reacquired rights 12 15,126 (9,838) 5,288 Internal-use software implementation costs 3 2,873 (2,043) 830 $ 19,568 $ (13,143) $ 6,425 December 31, 2021 (in thousands) Weighted Average Gross Carrying Accumulated Net Carrying Patents 12 $ 1,471 $ (1,176) $ 295 Acquired intellectual property and reacquired rights 12 15,126 (8,804) 6,322 Internal-use software implementation costs 3 2,873 (1,086) 1,787 $ 19,470 $ (11,066) $ 8,404 Amortization expense recognized by the Company related to intangible assets was $2.1 million, $2.1 million and $1.3 million for the years ended December 31, 2022, 2021 and 2020, respectively. Amortization expense as it relates to the amortization of acquired intellectual property and other intangible assets resides within amortization on the consolidated statements of operations. The estimated aggregate amortization expense for intangible assets over the next five fiscal years ending December 31, 2023 through December 31, 2027 is approximately $5.6 million.

Accounts payable and accrued li

Accounts payable and accrued liabilities	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accounts payable and accrued liabilities	Accounts payable and accrued liabilities Accounts payable and accrued liabilities are as follows: December 31, 2022 December 31, 2021 Employee accruals $ 20,157 $ 18,500 Commercial accruals 8,620 5,055 Accrued R&D projects 5,350 4,383 Trade payables 3,087 3,879 Other accrued liabilities 2,151 2,316 Income taxes payable 625 814 Total accounts payable and accrued liabilities $ 39,990 $ 34,947

License and Collaboration Agree

License and Collaboration Agreements	12 Months Ended
	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
License and Collaboration Agreements	License and Collaboration Agreements Otsuka Contract On December 17, 2020, the Company entered into a collaboration and license agreement with Otsuka for the development and commercialization of LUPKYNIS in the Otsuka Territories. As part of the agreement, the Company received an upfront cash payment of $50.0 million in 2020 for the license agreement and has the potential to receive up to $50.0 million in regulatory and pricing approval related milestones. The Company will provide semi-finished product of LUPKYNIS to Otsuka on a cost-plus basis, and will receive tiered royalties on future sales ranging from 10 to 20 percent (dependent on territory and achievement of sale thresholds) on net product sales by Otsuka, along with additional milestone payments based on the attainment of certain annual sales. In addition, certain collaboration services are to be provided to Otsuka on agreed upon rates. In furtherance of the collaboration and license agreement with Otsuka mentioned above, on August 1, 2022, the Company entered into a commercial supply agreement with Otsuka, formalizing the terms to supply semi-finished goods of LUPKYNIS to Otsuka in the Otsuka Territories, including capacity sharing of the monoplant. On September 15, 2022, the European Commission (EC) granted marketing authorization of LUPKYNIS. The centralized marketing authorization is valid in all EU member states as well as in Iceland, Liechtenstein, Norway and Northern Ireland. The approval triggered a $30.0 million milestone payment to the Company, which was recognized as collaboration revenue for the year ended December 31, 2022. For the year ended December 31, 2022 and December 31, 2021, the Company recognized $0.5 million and nil, respectively, of additional collaboration revenue from services provided under the agreement. Riptide License On August 17, 2021, AUR300 (M2 macrophage modulation via CD206 binding) was secured through a global licensing and research agreement with Riptide Bioscience, Inc. (Riptide), a private company. As part of the agreement, in 2021 the Company paid Riptide an upfront license fee of $6.0 million which was expensed as research and development on the condensed consolidated statements of operations. During the first quarter of 2022, Aurinia paid an additional $4.0 million to Riptide for the achievement of a onetime milestone. Additional payments are due upon certain development, clinical and regulatory milestones, and royalties will be payable upon commercialization.

Segment Information and Geograp

Segment Information and Geographic Data	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Segment Information and Geographic Data	Segment Information and Geographic Data As the operations comprise a single reporting segment, amounts disclosed in the consolidated financial statements represent those of the single reporting unit. We have elected to disclose geographical revenue from customers based on geographical location of contracting entity (and where the related payment stream of the customer is located). Revenues from our two main customers in the U.S. accounted in total of approximately 45% and 35% of the Company's total revenues for the year ending December 31, 2022. Our collaboration partner for sales outside the U.S. accounted for approximately 20% for the year ending December 31, 2022 of the Company's total revenues. Revenues from two customers accounted for approximately 56% and 43% for the year ending December 31, 2021. There was one customer that accounted for the vast majority of the revenues for the year ended December 31, 2020. Revenues by Geographic Location The following geographic information reflects revenue, net of adjustments, based on customer location: (in thousands) 2022 2021 2020 Revenue United States $ 102,460 $ 45,488 $ — Japan 31,481 — 50,000 Other 89 117 118 Total $ 134,030 $ 45,605 $ 50,118 Long-lived Assets by Location Long-lived assets by location consist of net property and equipment and right-of-use assets: (in thousands) December 31, 2022 December 31, 2021 Long-lived assets, net Canada $ 322 $ 625 United States 8,235 9,176 Total $ 8,557 $ 9,801

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Income (losses) before income taxes for the years ended December 31, 2022, 2021 and 2020 was as follows: (in thousands) 2022 2021 2020 Canada $ (112,359) $ (180,374) $ (61,024) Foreign 6,007 168 (41,750) $ (106,352) $ (180,206) $ (102,774) The components of income tax expense (benefit) consisted of the following for the years ended December 31, 2022, 2021 and 2020: (in thousands) 2022 2021 2020 Current: Canada $ — $ — $ — Foreign 1,828 760 (94) 1,828 760 (94) Deferred: Canada — — — Foreign — — — Total deferred — — — Income tax expense (benefit) $ 1,828 $ 760 $ (94) The Company's parent entity is located in Canada and therefore the Canadian statutory rate is utilized. The provision for income taxes varied from the income taxes provided based on the Canadian statutory rate of 26.7%, 26.8%, and 26.8% for the years ending December 31, 2022, 2021 and 2020, respectively. The Company's increase in tax expense is primarily driven by withholding tax payments of $1.2 million paid during 2022. 2022 2021 2020 Canada statutory income tax benefit 26.7 % 26.8 % 26.8 % Effect of tax rates on foreign jurisdictions 0.3 — (2.4) Withholding taxes (1.1) — — Impact of future rates and tax rate changes (0.1) (0.1) 6.1 Foreign tax credit 1.1 — — Non-deductible share-based compensation (8.1) (4.5) (4.5) Change in valuation allowance (21.5) (21.8) (26.0) Scientific Research and Experimental Development (SRED) 1.1 0.3 0.4 Other (0.1) (1.1) (0.3) Effective tax rate (1.7) % (0.4) % 0.1 % The net deferred tax assets (liabilities) consisted of the following for the years ending December 31, 2022 and 2021: (in thousands) 2022 2021 Deferred tax assets: Net operating loss carry-forwards $ 141,020 $ 120,274 Share issue costs 4,209 6,016 Intangible assets 1,400 1,086 SRED (Scientific Research and Experimental Development) 7,462 6,059 Capitalized research and development 1,663 — Deferred compensation 3,391 3,980 Accruals 2,887 2,653 Other 4,287 3,473 Gross deferred tax assets 166,319 143,541 Valuation allowance (164,514) (141,348) Total deferred tax assets 1,805 2,193 Deferred tax liabilities: Other (1,128) (1,356) Property and equipment and intangible assets (677) (837) Total deferred tax liabilities (1,805) (2,193) Net deferred tax assets (liabilities) $ — $ — The Company’s valuation allowance increased by $23.2 million in 2022 as compared to 2021 as a result of the additional pre-tax book losses. As of December 31, 2022, the Company has $518.1 million of Canada gross net operating loss (NOL) carryforwards with an expiration period of 2029 through 2042. As of December 31, 2022, the Company has approximately $5.8 million of Canada Investment Tax Credits and British Columbia Scientific Research and Experimental Development (SRED) with an expiration period of 2029 through 2042. As of December 31, 2022 the Company has approximately $10.1 million of U.S. federal gross NOL carryforwards that carryforward indefinitely, although limited to eighty percent of taxable income annually. Additionally, the Company has approximately $0.1 million of various state net operating loss carryforwards with varying expiration periods including carryforwards with indefinite carryforward periods and has approximately $0.4 million of U.K. gross net operating loss carryovers that carryforward indefinitely. Uncertain Tax Positions

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies The Company may, from time to time, be subject to claims and legal proceedings brought against it in the normal course of business. Such matters are subject to many uncertainties. Management believes the ultimate resolution of such contingencies will not have a material adverse effect on the consolidated financial statements. On December 18, 2020, the Company commenced an action in the United States District Court for the District of New Jersey against Sun Pharmaceutical Industries, Inc., Sun Pharmaceutical Industries, Ltd., and Sun Pharma Global FZE (collectively, "Sun"). The action was a claim for patent infringement under the patent laws of the United States arising from Sun's commercial manufacture, use, offer to sell, or sales within the United States, and/or importation into the United States of Sun's CEQUA product. In January 2023, we announced a settlement of this action with Sun. On February 24, 2022, Sun Pharmaceuticals Inc. petitioned for an IPR by the USPTO in respect of the '036 patent. The IPR was instituted on July 26, 2022. On January 25, 2023, the USPTO announced that the inter partes review had been terminated, based on a Joint Motion for Termination filed by us and Sun Pharmaceuticals Inc. On April 15, 2022, a purported shareholder class action complaint, Ortmann v. Aurinia Pharmaceuticals, Inc. et al., case no. 1:22-cv-02185, was filed in the United States District Court for the Eastern District of New York (Eastern District of New York), naming us and certain of our officers as defendants. The lawsuit alleges that we made materially false and misleading statements regarding our financial guidance and commercial prospects in violation of certain federal securities laws. The plaintiff seeks unspecified monetary damages on behalf of the putative class and an award of costs and expenses, including reasonable attorneys’ fees. On June 2, 2022, the case was transferred from the Eastern District of New York to the United States District Court for the District of Maryland. On February 20, 2023, the Court appointed a lead plaintiff and approved lead plaintiff’s selection of lead counsel. We expect that lead plaintiff will file an amended complaint, against which we intend to vigorously defend. Manufacturing Commitments The Company has various manufacturing agreements to support our commercial and clinical product supply requirements. We rely on Lonza, a third party manufacturer, to produce a portion of commercial and clinical quantities of our commercial and clinical drug substance requirements. We have firm orders with Lonza for future purchases of drug substance, with remaining total non-cancellable future commitments of approximately $29.3 million through 2024 of which $5.5 million was paid during 2022. If we terminate certain firm orders with Lonza without cause, we will be required to pay for drug substance scheduled for manufacture under our arrangement.

Deferred Compensation and Other

Deferred Compensation and Other Non-current Liabilities	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Deferred Compensation and Other Non-current Liabilities	Deferred Compensation and Other Non-current LiabilitiesThe Company recorded other non-current liabilities of $12.2 million and $16.0 million as of December 31, 2022 and December 31, 2021, respectively. The balance as of December 31, 2022 and December 31, 2021 primarily included deferred compensation arrangements whereby certain executive officers as of March 8, 2012 were provided with future potential employee benefit obligations for remaining with the Company, for a certain period of time. These obligations were also contingent on the occurrence of uncertain future events. At December 31, 2021, the other non-current liabilities also include milestone payments deemed probable to be paid in the future which were reclassed to current liabilities in 2022.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	Leases The Company has the following lease obligations: Victoria, British Columbia During August 2020, the Company signed a lease for commercial office space in Victoria, British Columbia for a new corporate headquarters that was expected to commence in April 2022. During the fourth quarter of 2020, the Company entered into 18-month facility and furniture leases for its existing corporate head office located in Victoria, British Columbia. The lease terms commenced on January 1, 2021 with an end date of August 31, 2022. On August 3, 2022, we provided notice of termination for the lease of the intended new corporate headquarters space in Victoria on the basis that the landlord's work was not completed by the time required under the lease. As a result of the termination, the Company expensed $0.3 million of Construction in Progress (CIP) cost that was related to the new corporate headquarters. On September 1, 2022, the fixed lease term ended for Aurinia's existing corporate headquarters and the Company exercised its right to enter into a month to month lease, of which expenses are incurred in SG&A. Rockville, Maryland During March 2020, the Company entered into a lease for its U.S. commercial office in Rockville, Maryland for a total of 30,531 square feet of office space. The lease has a remaining term of approximately 9 years and has an option to extend for two five-year periods after the 11 years has elapsed and has an option to terminate after seven years. As of December 31, 2022, the Company had a right-of-use asset of $4.9 million and lease liability of $8.0 million included in the consolidated balance sheets. As of December 31, 2021, the Company had a right of use asset of $5.2 million and lease liability of $8.6 million included in the consolidated balance sheets. During 2020, the Company received reimbursements for tenant leasehold improvements by the landlord in the amount of $2.3 million for the Maryland lease. The Company recorded leasehold improvement incentives as additions to the lease liability. The lease term commenced on March 12, 2020. When measuring the lease liability, the Company discounted lease payments using its incremental borrowing rate at March 12, 2020. The incremental borrowing rate applied to the lease liability on March 12, 2020 was 5.2% based on the financial position of the Company, geographical region and terms of lease. Edmonton, Alberta During October 2022, the Company entered into a long term lease in Edmonton for a total of 4,375 square feet of office space. The lease is a 6 year lease and has an option to renew of five years at prevailing market rates. The lease commenced on November 1, 2022 and the Company recorded the lease as an operating lease. The lease is not material to the Company's financial position. The Company incurs variable lease costs under the existing Victoria and Rockville leases. These costs include operation and maintenance costs included in SG&A and are expensed as incurred. The variable lease costs are not material to the Company's financial position. The operating lease costs for the years ended December 31, 2022 and December 31, 2021 are $1.0 million for both periods respectively. The weighted-average remaining lease term and discount rate for the years ended December 31, 2022 and December 31, 2021 are as follows: 2022 2021 Weighted average remaining lease term (in years) 8.7 9.5 Weighted average discount rate 5.3% 5.2% Supplemental cash flow information related to operating leases for the years ended December 31, 2022, December 31, 2021 and December 31, 2020 are as follows: (in thousands) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities $ (1,160) $ (646) $ (267) Initial recognition of operating lease right-of-use asset $ 57 $ 419 $ 5,804 Future maturities of operating lease liabilities as of December 31, 2022 are as follows: (in thousands) Operating Lease Payments 2023 $ 982 2024 1,113 2025 1,141 2026 1,169 2027 1,198 Thereafter 4,533 Total lease payments 10,136 Less: imputed interest (2,048) Total $ 8,088 On December 15, 2020, the Company entered into a collaborative agreement with Lonza to build a dedicated manufacturing capacity within Lonza’s existing small molecule facility in Visp, Switzerland. The dedicated facility (also referred to as "monoplant") will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand. Following U.S. regulatory approval of voclosporin in January 2021, the Company has commenced a capital expenditure payment program totaling approximately CHF 21.0 million. The first capital expenditure payment was made in February 2021 of $11.8 million (CHF 10.5 million) and was treated as an upfront lease payment and recorded under other non-current assets on the consolidated balance sheets. The second payment is not due until the facility fulfills the required operational qualifications which is estimated to be during the first half of 2023. Upon completion of the monoplant, the Company will maintain sole dedicated use of the monoplant by paying a required quarterly fixed facility fee. The Company expects to account for the arrangement as a finance lease under ASC 842. The present value of the minimum lease payments total approximately $85.0 million, beginning April 2023 and expiring in 2030, and are not included in the above table. The Company has entered into an equipment and facility finance lease for a backup manufacturing encapsulation site in Beinheim, France that has not yet commenced and is therefore, not included in the above table. As part of the agreement, the Company expects to make payments of approximately $0.9 million prior to lease commencement and the future value of minimum lease payments will total approximately $0.1 million.

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Shareholders' Equity	Shareholders' Equity Common shares: The Company has authorized an unlimited number of common shares with no par value. As of December 31, 2022, 2021 and 2020, 142.3 million, 141.6 million and 126.7 million Common Shares, respectively, were issued and outstanding. Each common share entitles the holder to one vote on all matters submitted to a vote of the Company’s shareholders. Common shareholders are not entitled to receive dividends unless declared by the Company’s Board of Directors. Any future determination regarding the declaration and payment of dividends is expected to be declared and paid in the Company's functional currency, the U.S. dollar. As discussed below from time to time, we intend to use the net proceeds from the sale of securities to fund our operations, which includes, but is not limited to, commercial activities, including our FDA related post approval commitments, manufacturing and packaging commercial drug supply, funding our supporting commercial infrastructure, advancing our R&D programs and funding our working capital obligations. November 19, 2021 ATM facility On November 19, 2021 the Company entered into an Open Market Sale Agreement (Sale Agreement) with Cantor Fitzgerald & Co. pursuant to which the Company may from time to time sell, through ATM offerings, common shares that would have an aggregate offering price of up to $250.0 million. Pursuant to this agreement the Company issued 10.2 million common shares at a weighted average price of $19.90 resulting in gross proceeds of $202.4 million as of December 31, 2021. The Company incurred share issue costs of approximately $5.6 million which included up to a 3% underwriting commission of $5.3 million and professional fees of $0.3 million directly related to the ATM. On February 25, 2022, the Company gave notice to Cantor Fitzgerald & Co. to terminate the Open Market Sale Agreement. No further sales occurred under the Open Market Sale Agreement. July 27, 2020 public offering On July 27, 2020 the Company completed a public offering of 13.3 million common shares at a price of $15.00 per share. Gross proceeds from this offering were $200.0 million and the share issue costs totaled an estimated $12.3 million which included a 6% underwriting commission of $12.0 million and professional fees of $0.3 million. Warrants: Warrant related to December 28, 2016 bought deal public offering: On December 28, 2016, the Company completed a $28.8 million Bought Deal public offering (2016 Public Offering). Under the terms of 2016 Public Offering, each Unit consists of one common share and one-half (0.50) of a common share purchase warrant (December 2016 Warrant). The Company issued 12.8 million Units at a subscription price per Unit of $2.25, exercisable for a period of five years from the date of issuance at an exercise price of $3.00. These December 2016 Warrants also meet the scope exceptions provided in ASC 815, Derivatives and Hedging , as they are indexed to the Company’s own shares, and therefore are accounted for under ASC 505, Equity . At initial recognition on December 28, 2016, the Company recorded a warrant in the amount of $7.2 million based on the estimated fair value of the December 2016 Warrants with allocated share issuance costs of $655 thousand recognized as a reduction of equity. During 2019, certain holders of these Warrants exercised at $3.00 per share for gross proceeds of $5.5 million. During 2020, a holder exercised 500 Warrants at $3.00 per share for gross proceeds of $2 thousand. During 2021, 1.7 million warrants had been exercised at $3.00 per share for gross proceeds of $0.3 million. Of these 1.7 million warrants, the Company issued 1.3 million common shares in lieu of 1.6 million warrants . All gross proceeds were recorded as an increase in cash and equity. The remaining 6,000 warrants expired as of December 31, 2021. There was no warrant activity during 2022. The warrant activity for 2021 is as follows: Number of warrants Balance at December 31, 2020 1,690 Warrants exercised (1,684) Warrants expired (6) Balance at December 31, 2021 —

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Share-Based Compensation	Shared-Based Compensation The Company's Amended and Restated Equity Incentive Plan (the Plan), which was adopted and approved by the Company's shareholders in June 2021, allows for an issuance of up to an aggregate of 23.8 million shares (inclusive of then outstanding awards) and provides for grants of stock options, performance awards (PAs) and restricted stock units (RSUs) that may be settled in cash and common shares. Also in June 2021, the Company's shareholders adopted and approved the Company's Employee Stock Purchase Plan (2021 ESPP), which allows for the issuance of up to 2.5 million shares of which 286 thousand and 37 thousand were purchased during 2022 and 2021. The 2021 ESPP is intended to qualify as an “employee stock purchase plan” under Section 423 of the Internal Revenue Code (the Code) but also permits the Company to include the employees, including non-United States employees, in offerings not intended to qualify under Section 423. The purpose of the 2021 ESPP is to provide eligible employees with opportunities to purchase the Company’s common shares at a discounted price. During 2022, the Company modified the 2021 ESPP for the current and future offerings. The new ESPP terms shortened the plan from four (4) purchases over a 24 month offering period to two (2) purchases over a 12 month offering period. Additionally, the ESPP now contains a rollover mechanism; that is, if the stock price on the purchase date is less than the offering price (as that is determined under the 2021 ESPP), that offering is then canceled and any participants are rolled into the new 12 month offering period at the lower price. As a result of the modification, we recorded incremental expense during 2022 which was immaterial to the consolidated statements of operations. In addition to stock options, PAs and RSUs granted under the Plan, the Company has granted certain stock options and RSUs as inducements material to new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducements were granted outside of the Plan during 2022. Stock Options The Plan requires the exercise price of each option not to be less than the closing market price of the Company’s common shares on the day immediately prior to the date of grant. The board of directors approves the vesting criteria and periods at its discretion. The options issued under the plan are accounted for as equity-settled share-based payments. The stock options and inducement stock options have a ten-year term and vest over three years with one-third of the shares vesting on the twelve month anniversary from the grant date, and the remaining options vesting in twenty-four The following table summarizes the number of stock options outstanding under the Plan for the years ended December 31, 2022. Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at December 31, 2021 12,074 $ 12.84 7.86 $ 121,141 Granted 3,913 $ 11.14 Exercised/released (77) $ 6.55 Cancelled/forfeited (2,615) $ 14.32 Outstanding at December 31, 2022 13,295 $ 12.09 7.74 $ 21 Options exercisable, December 31, 2022 8,345 $ 11.94 Vested and expected to vest, December 31, 2022 12,884 $ 11.98 The weighted average grant date fair value of stock options granted during the years ended December 31, 2022, 2021 and 2020 was $6.52, $7.34 and $5.58, respectively. The total fair value of options vested during the years ended December 31, 2022, 2021 and 2020 was $49.2 million, $24.9 million and $14.9 million, respectively. Total intrinsic value of options exercised was $0.9 million, $50.3 million and $13.1 million for years ended December 31, 2022, 2021 and 2020, respectively. In determining the fair value of the options granted, the Company uses the Black-Scholes option pricing model and reviews the following assumptions each reporting period: Expected Term - Expected term (in years) is based upon the contractual term, taking into account expected employee exercise and expected post-vesting employment termination behavior. Based on the Company's historical expected lives data and the growth during 2022 and 2021, the expected life extends further into the contractual life increasing the expected life. The increase of the expected life in 2022 is in line with historic data and what management expects in the future. Volatility - The Company considers historical volatility of its common shares in estimating its future stock price volatility. The expected life is used to determine market volatility of the underlying stock. The change in the volatility from in 2022 and 2021 was due to the Company's stock being more volatile. Given the growth of the Company, the expected life used to determine previous market volatility and comparable peer group reflects an appropriate estimate of future volatility. Risk-free interest rate - The risk-free interest rate for the expected life of the options was based on the yield available on government benchmark bonds with an approximate equivalent remaining term at the time of the grant. Dividend yield - The Company has never paid dividends on its common shares and has no plans to pay dividends on our common shares in the near future. Therefore, the Company dividend yield is zero. The following weighted average assumptions were used to estimate the fair value of the options granted during the years ended December 31, 2022, 2021 and 2020: 2022 2021 2020 Expected term (in years) 5 years 4 years 3 years Volatility 70 % 66 % 52 % Risk-free interest rate 2.06 % 0.46 % 0.55 % Dividend yield 0.0 % 0.0 % 0.0 % Performance Awards and Restricted Stock Units On October 23, 2020, the Company issued 439,000 PAs to executive management of the Company whose vesting was contingent upon meeting specific performance metrics based on the results for the year ended December 31, 2021. Each PA which vested entitled the participant to receive common shares on the basis of the performance metrics set. On March 18, 2021 performance metrics were set and formally communicated. Therefore, March 18, 2021 was the grant date and the fair value on the grant date was $13.56 . The PAs vested in 2022 and the participant was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. On August 6, 2021, the Company granted approximately 619,000 PAs and RSUs. The grant date for the PAs and RSUs was August 6, 2021 and the fair value on the grant date was $14.42 as this was the date performance measures were set and communicated to employees. The PAs vested on the employee's first anniversary of the grant date and the employee was required to achieve at least one of the performance metrics to obtain the portion of the award associated with the metric. The RSUs had no performance metrics and vested on the one year anniversary of the grant. During 2022, the Company has granted RSUs and intends to grant RSUs under the Plan, as well as inducements for certain new hires as discussed above. The RSUs are fair valued based on the market price of our common shares on the date of the grant. The RSUs and inducement RSUs shall vest in three equal annual installments on the first, second and third anniversary of the grant date. The following table summarizes the PA and RSU activity for the year ended December 31, 2022: Number of Shares Weighted-Average Grant Date Fair Value Unvested balance, December 31, 2021 347 $ 13.33 Granted 2,374 $ 11.16 Vested (305) $ 14.17 Forfeited (436) $ 12.21 Unvested balance, December 31, 2022 1,980 $ 10.84 Compensation Expense Share-based compensation expense for the years ended December 31, 2022, 2021 and 2020 totaled approximately $32.3 million, $31.2 million and $17.5 million, respectively, as shown in the table below. (in thousands) 2022 2021 2020 Research and development $ 3,271 $ 4,442 $ 3,730 Selling, general and administrative 28,438 26,432 13,615 Capitalized under inventories 591 369 109 Share-based compensation expense $ 32,300 $ 31,243 $ 17,454 The Company recorded approximately $11.4 million of share-based compensation expense related to PAs and RSUs during the year ended December 31, 2022. Unrecognized Share-Based Compensation Expense and Weighted Average Remaining Amortization Period As of December 31, 2022, the unrecognized share-based cost, and the estimated weighted-average amortization period, using the straight-line attribution method, was as follows (in thousands, except amortization period): Unrecognized share-based compensation expense Weighted average remaining amortization period (in years) Stock Options $ 10,869 1.12 Restricted Stock Units 10,584 1.52 ESPP 1,327 0.52 Total unrecognized share-based compensation expense $ 22,780 1.30

Net Loss Per Common Share

Net Loss Per Common Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Common Share	Net Loss Per Common Share Basic and diluted net loss per Common Share is computed by dividing net loss by the weighted average number of common shares outstanding. The numerator and denominator used in the calculation of basic and diluted net loss amounts per Common Share are as follows: 2022 2021 2020 Net loss for the year $ (108,180) $ (180,966) $ (102,680) Weighted average number of common shares outstanding 141,915 129,369 118,473 Net loss per common share (expressed in $ per share) $ (0.76) $ (1.40) $ (0.87) The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period: 2022 2021 2020 Outstanding stock options 13,295 12,074 14,047 Unvested performance awards — 64 — Unvested restricted units 1,980 191 — Warrants — — 1,690 15,275 12,329 15,737

Related-Party Transactions

Related-Party Transactions	12 Months Ended
	Dec. 31, 2022
Related Party Transactions [Abstract]
Related-Party Transactions	Related-Party TransactionsILJIN SNT Co., Ltd (ILJIN) was considered to be a related party due to their equity ownership of over 5% as per their public filings. During 2021, Aurinia paid $6.0 million upon achievement of specific milestones. The amount payable to ILJIN is nil as of December 31, 2022 and 2021.

Selected Quarterly Financial In

Selected Quarterly Financial Information (unaudited)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
Selected Quarterly Financial Information (unaudited)	Selected Quarterly Financial Information (unaudited) The following condensed quarterly financial information is for the years December 31, 2022 and 2021: (in thousands, except per share data) March 31, 2022 June 30, September 30, 2022 December 31, 2022 Total revenue, net $ 21,625 $ 28,191 $ 55,779 $ 28,435 Cost of sales and operating expenses 59,507 64,180 65,278 56,535 Loss from operations (37,882) (35,989) (9,499) (28,100) Net loss (37,630) (35,515) (8,989) (26,046) Basic and diluted loss per common share $ (0.27) $ (0.25) $ (0.06) $ (0.18) March 31, 2021 June 30, September 30, 2021 December 31, 2021 Total revenue $ 914 $ 6,620 $ 14,667 $ 23,404 Operating expenses 51,457 53,754 65,020 56,109 Loss from operations (50,543) (47,134) (50,353) (32,705) Net loss (50,379) (47,010) (50,255) (33,322) Basic and diluted loss per common share $ (0.40) $ (0.37) $ (0.39) $ (0.25)

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Subsequent Events On January 3, 2023, the Company announced that it had entered into a settlement agreement with Sun to file a joint motion to terminate the ongoing IPR and to settle the ongoing patent infringement litigation in the United States related to Sun's CEQUA product. The settlement agreement was contingent on receipt of termination of the IPR by the USPTO in respect of our '036 patent. On January 24, 2023, the Company announced that the USPTO allowed a method of use patent application titled IMPROVED PROTOCOL FOR TREATMENT OF LUPUS NEPHRITIS. This newly allowed patent application reflects the unique and proprietary dosing regimen of LUPKYNIS. Specifically, this patent further refines the method of using LUPKYNIS in combination with MMF and corticosteroids using eGFR as a method of pharmacodynamically dosing LUPKYNIS in patients with LN. The newly allowed application provides patent coverage that supplements our existing ‘036 patent. The claims in this additional patent add further specificity on dosing consistent with the FDA approved product label. This patent has the potential to provide an additional layer of patent protection for LUPKYNIS up to 2037. The Company intends to list this newly allowed patent in the Orange Book once issued. On January 25, 2023, the USPTO terminated the IPR it had instituted with respect to Aurinia's '036 patent.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of presentation	Basis of presentation: The Company follows accounting standards established by the Financial Accounting Standards Board (FASB) to ensure consistent reporting of financial condition, results of operations, and cash flows. References to generally accepted accounting principles (GAAP) or U.S. GAAP in these footnotes are to the FASB Accounting Standards Codification (ASC or the Codification). At the end of the second quarter of 2020, the Company determined that it no longer qualified as a Foreign Private Issuer under the SEC rules. As a result, beginning January 1, 2021 the Company is required to report with the SEC on domestic forms and comply with domestic company rules in the United States. Certain prior year amounts and notes to the consolidated financial statements have been reclassified to conform with the current year presentation. Other current assets and deferred revenue which were previously included in prepaid expenses and other current liabilities respectively, has been separately presented on the consolidated balance sheets as of December 31, 2022. Inventory reserves which was previously included in other, net on the consolidated statements of cash flows, has been separately presented for the years ended December 31, 2022 and December 31, 2021. Additionally, amortization of intangible assets which was presented separately on the statements of operations, has been included in SG&A and is included with depreciation on the consolidated statements of cash flows. Accounts payable and accrued liabilities and cash, cash equivalents and restricted cash and short-term investments balances have been reclassified in the notes to the consolidated financial statements. These reclassifications have no impact on previous reported total assets, total liabilities, net loss, stockholders’ equity or operating cash flows.
Principles of consolidation	Principles of consolidation: These financial statements present the consolidated financial position of the Company and its wholly owned subsidiaries, Aurinia Pharma U.S., Inc. (Delaware incorporated) and Aurinia Pharma Limited (UK incorporated) as of December 31, 2022 and 2021, and the results of operations and cash flows for the three years ended December 31, 2022, 2021 and 2020. All intercompany accounts and transactions have been eliminated in consolidation
Use of estimates	Use of estimates: The preparation of the accompanying financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure
Segment information	Segment information: The Company operates in one operating segment engaged in the research, development and commercialization of therapeutic drugs in which revenues are derived from product, license, and contract revenues. Operating segments are defined as components of an enterprise where separate financial information is evaluated regularly by the chief operating decision maker (CODM), the chief executive officer, in deciding how to allocate resources and assessing performance. The Company's CODM allocates resources and assesses performance based upon discrete financial information at the consolidated level.
Functional currency	Functional currency: The functional currency for the Company and all of its foreign subsidiaries is determined to be the U.S. dollar, therefore there is no currency translation adjustment upon consolidation as the remeasurement of gains or losses are recorded in the consolidated statement of operations. All monetary assets and liabilities denominated in a foreign currency are remeasured into U.S. dollars at the exchange rate on the balance sheet date. Non-monetary assets and liabilities (along with their related expenses) are translated at the rate of exchange in effect on the date assets were acquired. Monetary income and expense items are translated at the average foreign currency period. Foreign exchange gains and losses arising on translation or settlement of a foreign currency denominated monetary item are included in the consolidated statements of operations.
Fair value measurements	Fair value measurements: The Company's financial instruments consist primarily of cash and cash equivalents, short-term investments, accounts receivable, accounts payable and accrued liabilities. The Company has determined the carrying values of these financial instruments approximate their fair value because of the relatively short period to maturity of the instruments.
Concentration of credit risk	Concentration of credit risk: Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash equivalents and restricted cash, short term investments and accounts receivable, net. The Company attempts to minimize the risks related to cash and cash equivalents and restricted cash and investments by investing in a range of financial instruments. The Company established guidelines related to credit ratings and maturities intended to safeguard principal balances, earn a return on investments and to maintain liquidity. The Company's investment portfolio is maintained in accordance with its investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. The Company does not enter into any investment transaction for trading or speculative purposes. The Company’s investment policy limits investments to certain types of instruments such as certificates of deposit, money market instruments, obligations issued by the U.S. government and U.S. government agencies as well as high quality corporate debt securities, and places restrictions on maturities and concentration by type and issuer. The Company maintains cash balances in excess of amounts insured by the Federal Deposit Insurance Corporation and Canada Deposit Insurance Corporation and concentrated within a limited number of financial institutions. The accounts are monitored by management to mitigate the risk. The Company is exposed to financial risk related to the fluctuation of foreign currency exchange rates which could have a material effect on its future operating results or cash flows. Foreign currency risk is the risk that variations in exchange rates between the U.S. dollar and foreign currencies, primarily with the Canadian dollar, Swiss Franc and Great British Pound will affect the Company's operating and financial results. The Company holds the majority of its cash and cash equivalents in U.S. dollars and the majority of its expenses, including commercial and clinical trial costs are also denominated in U.S. dollars, which mitigates the risk of material foreign exchange fluctuations. Major customers : The Company currently has two main customers for U.S. commercial sales of LUPKYNIS and a collaboration partner for sales of LUPKYNIS in the Otsuka Territories. Revenues from the Company's two main customers in the U.S. accounted for approximately 45% and 35%, respectively, of the Company's total revenues for the year ended December 31, 2022. The two main customers accounted for 100% of the Company’s accounts receivable, net balance as of December 31, 2022. Otsuka, the Company's collaboration partner for sales outside the U.S. accounted for approximately 20% of the Company's total revenue for the year ended December 31, 2022. In late March 2022, the Company provided a nominal additional discount to both of its two main U.S. customers, applicable for the 2022 calendar year, in connection with holding additional amounts of LUPKYNIS on hand due to supply chain concerns. In December 2022, the Company extended the nominal discount to the end of 2023. Such discounts, or any future discounts, may result in reduced sales to these customers in subsequent periods and substantial fluctuations in our revenues from period to period. The Company monitors economic conditions, the creditworthiness of customers and government regulations and funding, both domestically and abroad. The Company regularly communicates with its customers regarding the status of receivable balances. Global economic conditions and customer specific factors may require the Company to periodically re-evaluate the collectability of its receivables and based on this evaluation the Company could potentially incur credit losses. The Company has had no historical write-offs related to our customers or receivables.
Accounts receivable, net	Accounts receivable, net: Accounts receivables are stated at their net realizable value. The Company's accounts receivable represents amounts due to the Company from product sales and from its Otsuka collaboration agreement (Note 10). Sales and services that have not been invoiced as of the balance sheet date are recorded as unbilled accounts receivable. As of December 31, 2022 and December 31, 2021, accounts receivable, net are $13.5 million and $15.4 million, respectively. The timing between the recognition of revenue for product sales and the receipt of payment is not significant. The Company's standard credit terms range from 30 to 45 days. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between the transfer of the promised good to the customer and receipt of payment will be one year or less. The Company's estimates the allowance for doubtful accounts using the current expected credit loss (CECL) model. Under the CECL model, the allowance for doubtful accounts reflects the net amount expected to be collected from the account receivables. The Company evaluates the collectability of these cash flows based on the asset’s amortized cost, the risk of loss even when that risk is remote, losses over an asset’s contractual life, and other relevant information available to us. Accounts receivable balances are written off against the allowance when it is probable that the receivable will not be collected. Given the nature of the Company's accounts receivable, it determined that an allowance for doubtful accounts was nil at December 31, 2022 and December 31, 2021. Accounts receivables are recorded net of estimates of variable consideration for which reserves are established and which result from discounts that are offered within contracts between us and two specialty pharmacies and one specialty distributor in the United States. These reserves are recorded as a reduction of accounts receivable.
Cash and cash equivalents and Restricted cash	Cash and cash equivalents: The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. Cash and cash equivalents consist primarily of operating accounts, money market funds and bank money market accounts which are recorded at fair value. Cash and cash equivalents totaled $94.2 million as of December 31, 2022. The Company has invested its cash reserves in short term U.S. dollar denominated, fixed rate, highly liquid and highly rated financial instruments such as treasury notes, banker acceptances, bank bonds, and term deposits. Restricted cash : Restricted cash consists of the 2021 Employee Share Purchase Plan (ESPP) deposits of $0.1 million and $0.3 million as of December 31, 2022 and December 31, 2021, respectively.
Investments	Investments: The Company classifies its debt securities as either held to maturity or available-for-sale in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 320, Investments — Debt Securities . Investments classified as held to maturity are carried at amortized cost when management has the positive intent and ability to hold them to maturity. Investments classified as available-for-sale are carried at fair value with unrealized losses reported in other comprehensive loss within shareholders’ equity. Realized losses on available-for-sale securities are recorded in other income (expense), net. Interest income (expense) is recorded separately on the consolidated statements of operations. The cost of securities sold is based on the specific-identification method.
Intangible assets	Intangible assets: Intangible assets are amortized over their useful lives using methods that correlate to the pattern in which the economic benefits are expected to be realized. All intangible assets are amortized on a straight-line basis. The Company evaluates the estimated remaining useful life of its intangible assets and whether events or changes in circumstances warrant a revision to the remaining period of amortization. The carrying amounts of these assets are periodically reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of these assets may not be recoverable. Refer to the long-lived assets section below for impairment considerations. Acquired intellectual property and patents External patent costs specifically associated with preparing, filing, obtaining and protecting patents are capitalized and amortized straight-line over the shorter of the estimated useful life and the patent life, commencing in the year of the grant of the patent. Other intellectual property expenditures are recorded as R&D expenses on the consolidated statements of operations as incurred. Patents do not contain the option to extend or renew. External legal costs incurred to defend a patent are capitalized when it is believed that the future economic benefit of the patent will be increased and a successful defense is probable.
Property, plant and equipment	Property, plant and equipment: Property, plant and equipment are recorded at cost and are depreciated using the straight-line method. Expenditures for additions are capitalized and leasehold improvements are amortized over the lesser of the expected lease term or the estimated useful life of the improvement. Expenditures for maintenance and repairs are charged to expense as incurred; however, maintenance and repairs that improve or extend the life of existing assets are capitalized. The carrying amount of assets disposed of and the related accumulated depreciation are eliminated from the accounts in the year of disposal. Gains or losses from property and equipment disposals are recognized in the year of disposal.
Recoverability and impairment of long-lived assets	Recoverability and impairment of long-lived assets: ASC Topic 360 requires long-lived assets, including definite-lived intangible assets, to be evaluated for impairment when events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The judgments made related to the expected useful lives of long-lived assets, definitions of lease terms and the Company’s ability to realize undiscounted cash flows in excess of the carrying amounts of these assets are affected by factors such as the ongoing maintenance and improvements of the assets, changes in economic conditions, changes in usage or operating performance and other factors. If indicators are present, assets are grouped to the lowest level for which identifiable cash flows are largely independent of other asset groups and cash flows are estimated for each asset group over the remaining estimated life of each asset group. If the undiscounted cash flows estimated to be generated by the asset group are less than the asset’s carrying amount, impairment is recognized in the amount of excess of the carrying value over the fair value.
Leases	Leases : The Company assesses all contracts at inception to determine whether a lease exists. The Company’s leases are all classified either as operating or finance leases per ASC 842. The Company leases office space under operating leases that typically provide for the payment of minimum annual rentals and may include scheduled rent increases. The Company also entered into a manufacturing agreement that contained an embedded lease of a dedicated manufacturing facility that will be accounted for as a finance lease once lease commencement begins (see Note 15). The Company made an accounting policy election, the practical expedient that allows lessees to treat the lease and non-lease components of leases as a single lease component. Leases with an initial term of 12 months or less are not recorded on the Company's consolidated balance sheets and to recognize those lease payments on a straight-line basis in its consolidated statements of operations. Fixed costs associated with these arrangements are disclosed in Note 15 of the financial statements.
Deferred Compensation Arrangements	Deferred Compensation Arrangements : The Company has recorded deferred compensation arrangements in liabilities for estimated future employee benefits relating to applicable historical employment arrangements. The deferred compensation arrangements are part of the resolution of the board of directors of the company dated March 8, 2012. Pursuant to ASC Topic 710, the Company recognizes future benefits provided by employee retention arrangements, as deferred compensation, which is recognized when the Company determines that it is probable to make future payments. The deferred compensation is based on an income approach for the estimated future net revenues of voclosporin using an internal risk-adjusted net present value of the future payments to be made to the individuals. The Company is required to use judgment to determine the most appropriate model to use to measure the deferred compensation liability and is required to use significant judgment and estimates in determining the inputs into the model. The royalty rates applied to the net revenue are dependent on the type of net revenue earned, which includes product sales and royalty revenue. There are multiple unobservable and inherently uncertain inputs. The determination of this deferred compensation is subject to significant judgments and estimates in determining the assumptions related to future net revenues and the determination of the discount rate for the net present value calculation. The net revenue estimate for the United States includes assumptions related to the number of patients being treated (including patients who initially start taking the product but subsequently discontinue), dosing adjustments, duration of treatment, timing of generics and competitors entering the market, market penetration and potential future use in new indications. Additional variables for ex-U.S. geographies include timing of approval in ex-U.S. territories, escalating royalty rates, net pricing, government payor coverage of the product, and market penetration. In determining the estimate for ex-U.S. revenues, the Company relies on forecasts provided by its collaboration partner. Management developed the model and inputs in conjunction with their internal scientific team and utilized third party scientific studies, information provided by third party consultants engaged by the Company, information from medical and pharmacy claims databases and research papers as sources to develop their inputs; application and usage of these inputs is also informed by product sales and distribution data, ongoing market research fielded by the company and third parties, and our continually evolving understanding of the market as the U.S. launch progresses. Management believes the liability is based on reasonable assumptions; however, these assumptions may be incomplete or inaccurate and unanticipated events and circumstances may occur. There are numerous significant inputs into the model all of which individually or in combination may result in a material change to the obligation. Initially, these obligations are measured at the present value of expected future payments to be made in respect of services provided by employees up to the end of the reporting periods. Subsequent re-measurements as a result of performance obligations met by the Company or changes in assumptions are recognized in the consolidated statement of operations.
Contingencies	Contingencies: In the normal course of business, the Company may be subject to loss contingencies, such as legal proceedings, amounts arising from contractual arrangements and claims arising out of the Company’s business that cover a wide range of matters, including, among others, government investigations, shareholder lawsuits, product and environmental liability, and tax matters. In accordance with ASC Topic 450, Accounting for Contingencies , (ASC 450), the Company records accruals for such loss contingencies when it is probable that a liability will be incurred, and the amount of loss can be reasonably estimated. The Company, in accordance with this guidance, does not recognize gain contingencies until realized or realizable.
Common Shares	Common Shares: The Company’s shares have no par value and therefore, upon issuance of shares, all amounts related to the shares are credited to common shares on the balance sheet. The value of common shares includes cash amounts received or paid for the shares and the fair value of equity awards and warrants. Amounts for common shares are offset by share issue costs associated with equity offerings.
Inventories	Inventories: Inventories are valued under a standard costing methodology on a first-in, first-out basis and are stated at the lower of cost or net realizable value. The Company capitalizes inventory costs related to products to be sold in the ordinary course of business. The Company makes a determination of capitalizing inventory costs for a product based on, among other factors, status of regulatory approval, information regarding safety, efficacy and expectations relating to commercial sales and recoverability of costs. Capitalized costs of inventories mainly include third party manufacturing costs, transportation, storage, insurance and allocated internal labor. The Company assesses recoverability of inventory each reporting period to determine any write down to net realizable value resulting from excess or obsolete inventories.
Revenue Recognition	Revenue Recognition: Pursuant to Accounting Standards Codification Topic 606, Revenue from Contracts with Customers (ASC 606), the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. Revenue is recognized through a five-step process: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those that are performance obligations. Revenue is recognized for the applicable performance element when each distinct performance obligation is satisfied. Product Revenues In the United States (and territories), the Company sells LUPKYNIS primarily to a limited number of specialty pharmacies and specialty distributors. These customers subsequently resell the Company's products to health care providers and patients. Revenues from product sales are recognized when the customer obtains control of the Company's product, which typically occurs upon delivery to the customer. Reserves for discounts and allowances: Product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established. These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). The Company's estimates of reserves established for variable consideration are calculated based upon utilizing the expected value method. The transaction price, which includes variable consideration reflecting the impact of discounts and allowances, may be subject to constraint and is included in the net sales price only to the extent that it is probable that a significant reversal of the amount of the cumulative revenues recognized will not occur in a future period. Amounts related to such items are estimated at contract inception and updated at the end of each reporting period as addition information becomes available. Significant judgment is required in estimating variable consideration. In making these estimates, the Company considers historical data, including patient mix and inventory sold to our customers that has not yet been dispensed. The Company uses a data aggregator and historical claims to estimate variable consideration for inventory sold to our customers, including specialty pharmacies and specialty distributors, that has not yet been dispensed. Actual amounts may ultimately differ from the Company's estimates. If actual results vary, the Company adjusts these estimates, which could have an effect on earnings in the period of adjustment. As of December 31, 2022, the Company did not have any material adjustments to variable consideration estimates based on actual results. More specifically, these adjustments include the following: Prompt Pay Discounts: The Company generally provides invoice discounts on product sales to its customers for prompt payment. The Company estimates that its customers will earn these discounts and fees, and deducts the full amount of these discounts and fees from its gross product revenues and accounts receivable at the time such revenues are recognized. Customer Fees: The Company pays certain customer fees, such as fees for certain data that customers provide to the Company. The Company records fees paid to its customers as a reduction of revenue, unless the payment is for a distinct good or service from the customer and the Company can reasonably estimate the fair value of the goods or services received. If both conditions are met, the Company records the consideration paid to the customer as SG&A expense. Government Rebates: The Company estimates its government rebates, primarily Medicaid and Medicare rebates based upon a range of possible outcomes that are probability-weighted for the estimated payor mix. These reserves are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued expenses on the consolidated balance sheet. Medicaid rebates relate to the Company's estimated obligations to states under established reimbursement arrangements. Rebate accruals are recorded in the same period that the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability, which is included in other current liabilities. The Company's liability for Medicaid rebates consists of estimates for claims that a state will make for the current quarter, claims for prior quarters that have been estimated for which an invoice has not been received, invoices received for claims from the prior quarters that have not been paid and an estimate of potential claims that will be made for inventory that exists in the distribution channel at period end. For Medicare, the Company also estimates the number of patients in the prescription drug coverage gap for whom the Company will owe an additional liability under the Medicare Part D program. The Company’s liability for these rebates consists of invoices received for claims from prior quarters that have not been paid or for which an invoice has not yet been received, estimates of claims for the current quarter, and estimated future claims that will be made for product that has been recognized as revenue, but remains in the distribution channel inventories at the end of each reporting period. Co-payment Assistance: Co-payment assistance represents financial assistance to qualified patients, assisting them with prescription drug co-payments required by insurance. The program is administered by the specialty pharmacies. The calculation of the accrual for co-payment assistance is based on the co-payments administered on the Company's behalf by the specialty pharmacies. Payor Rebates and Administration Fees: Payor rebates and administration fees represent our estimated obligations to third parties, primarily benefit managers. Accruals are recorded in the same period the related revenue is recognized, resulting in a reduction of product revenue and the establishment of a liability. These rebates and fees result from formulary position and price increase limit allowances (price protection) and administration fees. The calculation of the accrual for these items are based on the estimated payors buying patterns and the resulting applicable contractual rebate rate(s) to be earned over a contractual period. Manufacturing Supply Services: The Company also has agreements with its partners that include a promise for future supply of drug substance or drug product for either clinical development or commercial supply at the licensee’s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, they are accounted for as separate performance obligations. If the Company is entitled to additional payments when the licensee exercises these options, any additional payments are recorded as product sales when the licensee obtains control of the goods, which is typically upon delivery. Certain agreements include terms where the Company can partially bill for drug substance used before the manufacturing cycle is complete, resulting in a deferred revenue which is to be recognized once delivery occurs. License and Collaboration Revenue The Company enters into out-licensing agreements that are within the scope of ASC 606, under which it licenses certain rights to its product candidates to third parties. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments, payments for manufacturing supply services the Company provides through its contract manufacturers, and royalties on net sales of licensed products. Each of these payments results in license, collaboration and other revenues, except for revenues from royalties on net sales of licensed products, which are classified as royalty revenues. In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Licenses of Intellectual Property : If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Milestone Payments: At the inception of each arrangement that includes development or commercial sales milestone payments, the Company evaluates whether the milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. The transaction price is then allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, the Company re-evaluates the probability of achievement of such development milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect license, collaboration and other revenues and earnings in the period of adjustment. Other Services Revenue : The Company’s agreements may include R&D, manufacturing or other services to be performed by the Company on behalf of the counterparty. If these services are determined to be distinct from the other promises or performance obligations identified in the arrangement, the Company recognizes the transaction price allocated to these services as revenue either over time based on an appropriate measure of progress when the performance by the Company does not create an asset with an alternative use and the Company has an enforceable right to payment for the performance completed to date or at a point in time as the related performance obligations are satisfied. Royalty Revenue For arrangements that include sales-based royalties, revenue is recognized when the underlying product sales have occurred. Revenue is recorded based on estimated quarterly net sales reports provided by our partner. Differences between actual results and estimated amounts are adjusted in the period in which they become known, which typically follows the quarterly period in which the estimate is made. Sales based milestone payments are recognized in the period once the milestone objectives have been achieved. Costs to obtain a contract As the majority of our contracts are short-term in nature, sales commissions are generally expensed when incurred as the amortization period would have been less than one year. The costs are recorded within SG&A. Cost of sales : Cost of sales consist primarily of cost of inventories for LUPKYNIS and semi-finished product, which mainly includes third party manufacturing costs, transportation, storage, insurance and allocated internal labor. Cost of sales also includes costs related to collaboration revenues.
Research and development costs	Research and development costs: R&D costs are accounted for in accordance with ASC Topic 730, Research and Development , (ASC 730) and are expensed as incurred. R&D costs consist primarily of the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for R&D activities, including nonclinical studies, clinical trials, manufacturing costs and professional services. The costs of services performed by others in connection with the R&D activities of the Company, including R&D conducted by others on behalf of the Company, shall be included in R&D costs and expensed as the contracted work is performed. We accrue the costs incurred under our agreements with these third parties based on actual work completed in accordance with agreements established with these third parties. We determine the accruals for R&D costs through monitoring invoices received and discussions with internal personnel and external service providers as to the progress or stage of completion of the clinical studies and the agreed-upon fee to be paid for such services. Where contingent milestone payments are due to third parties under R&D arrangements or license agreements, the milestone payment obligations are expensed when the milestone results are probable to be achieved. R&D expenses for the years ended December 31, 2022, 2021 and 2020, were $45.0 million, $51.1 million and $50.3 million, respectively, and are included in total cost of sales and operating expenses on the accompanying consolidated statements of operations.
Selling, general and administrative expenses	Selling, general and administrative expenses : The Company's SG&A expenses include commercial and allocated administrative personnel, corporate facility and external costs required to support the marketing and sales of LUPKYNIS. These SG&A costs include corporate facility operating expenses and allocated depreciation; commercial, marketing, advertising, pharmacovigilance, publications, tradeshows, advisory boards, samples and operations in support of LUPKYNIS; patient assistance program costs; human resources; finance, legal, information technology and support personnel expenses; and other corporate costs such as telecommunications, insurance, audit and government affairs. We expense SG&A expenses as they are incurred. The Company uses a third-party logistics provider to perform a full order to cash service, which includes warehousing and shipping directly to two specialty pharmacies and receiving orders from a specialty distributor for shipping to hospitals, on our behalf. As such, since these costs are not integral to bringing the inventories to a salable condition, we elected not to treat shipping and handling costs as a fulfillment activity. Shipping and handling costs related to order fulfillment are recorded in SG&A expenses.
Advertising costs	Advertising and marketing costs are expensed as incurred and included in SG&A.
Share-based compensation	Shared-based compensation: The Company follows ASC Topic 718, Compensation - Stock Compensation (ASC 718), which requires the measurement and recognition of compensation expense, based on estimated fair values, for all share-based awards made to employees and directors. The Company records compensation expense based on the fair value on the grant date using the graded accelerated vesting method for all share-based payments related to stock options, performance awards (PAs), restricted stock units (RSUs) and purchases under the Company's 2021 ESPP. The estimated fair value of performance-based awards is measured on the grant date and is recognized when it is determined that it is probable that the performance condition will be achieved. The Company has elected a policy for all share-based awards to estimate forfeitures based on historical forfeiture experience at the time of grant and revise in subsequent periods if actual forfeitures differ from those estimates.
Income taxes	Income taxes: The Company accounts for income taxes under the asset and liability method in accordance with ASC Topic 740, Income Taxes (ASC 740). Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The portion of any deferred tax asset for which it is more likely than not that a tax benefit will not be realized must then be offset by recording a valuation allowance. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured
Recently adopted accounting pronouncements	Recently adopted accounting pronouncements In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments . The standard requires that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The adoption of the standard as of January 1, 2020 did not have a material impact on the Company’s consolidated financial statements. In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirement for Fair Value Measurement . Topic 820 requires to disclose transfers into and out of Level 3 of the fair value hierarchy and purchases and issues of Level 3 assets and liabilities. For investments in certain entities that calculate net asset value, an entity is required to disclose the timing of liquidation of an investee’s assets and the date when the restrictions from redemptions might lapse only if the investee has communicated the timing to the entity or announced the timing publicly. The new standard also amends that the measurement uncertainty disclosure is to communicate information about the uncertainty in measurement as of the reporting date. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU 2014-09, Revenue from Contracts with Customers (Topic 606) . The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements. In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40)-Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract , which aligns the accounting for implementation costs incurred in a hosting arrangement that is a service contract with the accounting for implementation costs incurred to develop or obtain internal-use software under ASC 350-40, in order to determine which costs to capitalize and recognize as an asset and which costs to expense. ASU 2018-15 is effective for annual reporting periods, and interim periods within those years, beginning after December 15, 2019, and can be applied either prospectively to implementation costs incurred after the date of adoption or retrospectively to all arrangements. The Company adopted ASU 2018-15 effective January 1, 2020 and applied the standard prospectively to implementation costs incurred in its cloud computing arrangements. In November 2018, the FASB issued ASU No. 2018-18, Collaborative Arrangement (Topic 808): Clarifying the Integration between Topic 808 and Topic 606. The new standard clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. Further, the new standard adds unit-of-account guidance to Topic 808 to align with the guidance in Topic 606 when an entity is assessing whether the collaborative arrangement or part of the arrangement is within the scope of Topic 606. The new standard requires that in transactions with a collaborative arrangement participant that is not directly related to sales to third parties, presenting under Topic 606 is precluded if the collaborative arrangement participant is not a customer. The new standard is effective for fiscal years beginning after December 15, 2019. The standard should be applied retrospectively to the date of initial application of ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) . The Company elected to adopt the amendment as of January 1, 2020, which did not have a material impact on the consolidated financial statements. In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) : Simplifying the Accounting for Income Taxes, which clarifies and simplifies certain aspects of the accounting for income taxes. The standard is effective for years beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2020. The Company adopted the ASU effective January 1, 2021 with no material impact on the consolidated financial statements. In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 832) : Disclosures by Business Entities about Government Assistance, which requires business entities to make annual disclosures about transactions with a government (including government assistance) by analogizing to a grant or contribution accounting model. The required

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table summarizes the financial assets (cash, cash equivalents, restricted cash and short-term investments) measured at fair value on a recurring basis: December 31, 2022 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 94,172 $ — $ — $ 94,172 U.S. agency security — 4,948 — 4,948 Corporate bond — 104,080 — 104,080 Commercial paper — 125,187 — 125,187 Treasury bill — 12,282 — 12,282 Treasury bond — 42,220 — 42,220 Yankee bond — 6,501 — 6,501 Total financial assets $ 94,172 $ 295,218 $ — $ 389,390 December 31, 2021 (in thousands) Level 1 Level 2 Level 3 Total Financial assets: Cash, cash equivalents and restricted cash $ 231,900 $ — $ — $ 231,900 Certificates of deposit — 3,140 — 3,140 Corporate bond — 21,820 — 21,820 Commercial paper — 206,724 — 206,724 Treasury bill — 2,494 — 2,494 Total financial assets $ 231,900 $ 234,178 $ — $ 466,078

Cash, Cash Equivalents and Re_2

Cash, Cash Equivalents and Restricted Cash and Short-Term Investments (Tables)	12 Months Ended
	Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]
Investments	December 31, 2022 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 94,172 $ — $ — $ 94,172 U.S. agency security 4,951 — (3) 4,948 Corporate bond 104,174 — (94) 104,080 Commercial paper 125,255 — (68) 125,187 Treasury bill 12,290 — (8) 12,282 Treasury bond 42,301 — (81) 42,220 Yankee bond 6,503 — (2) 6,501 Total cash, cash equivalents, restricted cash and short-term investments $ 389,646 $ — $ (256) $ 389,390 December 31, 2021 (in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value Cash, cash equivalents and restricted cash $ 231,900 $ — $ — $ 231,900 Certificates of deposit 3,144 — (4) 3,140 Corporate bond 2,593 — (1) 2,592 Commercial paper 206,764 — (40) 206,724 Treasury bill 2,496 — (2) 2,494 Total $ 446,897 $ — $ (47) $ 446,850 Held-to-maturity securities corporate bond 19,228 19,228 Total cash, cash equivalents, restricted cash and short-term investments $ 466,078

Inventories, net (Tables)

Inventories, net (Tables)	12 Months Ended
	Dec. 31, 2022
Inventory Disclosure [Abstract]
Schedule of Inventory	The components of inventories, net are as follows: (in thousands) December 31, 2022 December 31, 2021 Raw materials $ 2,217 $ 2,217 Work in process 21,059 12,566 Finished goods 1,476 4,543 Total inventories, net $ 24,752 $ 19,326

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2022
Receivables [Abstract]
Prepaid Expenses and Other Current Assets	Prepaid expenses are as follows: (in thousands) December 31, 2022 December 31, 2021 Prepaid assets $ 5,451 $ 5,316 Prepaid deposits 6,330 4,762 Prepaid insurance 1,799 1,632 Total prepaid expenses $ 13,580 $ 11,710

Property and Equipment, net (Ta

Property and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	Property and equipment, net are as follows: (in thousands) Estimated Useful Life December 31, 2022 December 31, 2021 Construction in progress — $ 255 $ 393 Leasehold improvements Shorter of term of the lease or estimated useful life 2,978 2,978 Office equipment 5 645 645 Furniture 7 976 976 Computer equipment 3 251 262 5,105 5,254 Less accumulated depreciation (1,455) (836) Property and equipment, net $ 3,650 $ 4,418

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	The following table summarizes the carrying amount of intangible assets, net of accumulated amortization. December 31, 2022 (in thousands) Weighted Average Gross Carrying Accumulated Net Carrying Patents 12 $ 1,569 $ (1,262) $ 307 Acquired intellectual property and reacquired rights 12 15,126 (9,838) 5,288 Internal-use software implementation costs 3 2,873 (2,043) 830 $ 19,568 $ (13,143) $ 6,425 December 31, 2021 (in thousands) Weighted Average Gross Carrying Accumulated Net Carrying Patents 12 $ 1,471 $ (1,176) $ 295 Acquired intellectual property and reacquired rights 12 15,126 (8,804) 6,322 Internal-use software implementation costs 3 2,873 (1,086) 1,787 $ 19,470 $ (11,066) $ 8,404

Accounts payable and accrued _2

Accounts payable and accrued liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Schedule of Accrued Liabilities	Accounts payable and accrued liabilities are as follows: December 31, 2022 December 31, 2021 Employee accruals $ 20,157 $ 18,500 Commercial accruals 8,620 5,055 Accrued R&D projects 5,350 4,383 Trade payables 3,087 3,879 Other accrued liabilities 2,151 2,316 Income taxes payable 625 814 Total accounts payable and accrued liabilities $ 39,990 $ 34,947

Segment Information and Geogr_2

Segment Information and Geographic Data (Tables)	12 Months Ended
	Dec. 31, 2022
Segment Reporting [Abstract]
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas	The following geographic information reflects revenue, net of adjustments, based on customer location: (in thousands) 2022 2021 2020 Revenue United States $ 102,460 $ 45,488 $ — Japan 31,481 — 50,000 Other 89 117 118 Total $ 134,030 $ 45,605 $ 50,118
Long-lived Assets by Geographic Areas	Long-lived assets by location consist of net property and equipment and right-of-use assets: (in thousands) December 31, 2022 December 31, 2021 Long-lived assets, net Canada $ 322 $ 625 United States 8,235 9,176 Total $ 8,557 $ 9,801

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Income (Losses) before Income Tax, Domestic and Foreign	Income (losses) before income taxes for the years ended December 31, 2022, 2021 and 2020 was as follows: (in thousands) 2022 2021 2020 Canada $ (112,359) $ (180,374) $ (61,024) Foreign 6,007 168 (41,750) $ (106,352) $ (180,206) $ (102,774)
Schedule of Components of Income Tax Expense (Benefit)	The components of income tax expense (benefit) consisted of the following for the years ended December 31, 2022, 2021 and 2020: (in thousands) 2022 2021 2020 Current: Canada $ — $ — $ — Foreign 1,828 760 (94) 1,828 760 (94) Deferred: Canada — — — Foreign — — — Total deferred — — — Income tax expense (benefit) $ 1,828 $ 760 $ (94)
Schedule of Effective Income Tax Rate Reconciliation	The provision for income taxes varied from the income taxes provided based on the Canadian statutory rate of 26.7%, 26.8%, and 26.8% for the years ending December 31, 2022, 2021 and 2020, respectively. The Company's increase in tax expense is primarily driven by withholding tax payments of $1.2 million paid during 2022. 2022 2021 2020 Canada statutory income tax benefit 26.7 % 26.8 % 26.8 % Effect of tax rates on foreign jurisdictions 0.3 — (2.4) Withholding taxes (1.1) — — Impact of future rates and tax rate changes (0.1) (0.1) 6.1 Foreign tax credit 1.1 — — Non-deductible share-based compensation (8.1) (4.5) (4.5) Change in valuation allowance (21.5) (21.8) (26.0) Scientific Research and Experimental Development (SRED) 1.1 0.3 0.4 Other (0.1) (1.1) (0.3) Effective tax rate (1.7) % (0.4) % 0.1 %
Schedule of Deferred Tax Assets and Liabilities	The net deferred tax assets (liabilities) consisted of the following for the years ending December 31, 2022 and 2021: (in thousands) 2022 2021 Deferred tax assets: Net operating loss carry-forwards $ 141,020 $ 120,274 Share issue costs 4,209 6,016 Intangible assets 1,400 1,086 SRED (Scientific Research and Experimental Development) 7,462 6,059 Capitalized research and development 1,663 — Deferred compensation 3,391 3,980 Accruals 2,887 2,653 Other 4,287 3,473 Gross deferred tax assets 166,319 143,541 Valuation allowance (164,514) (141,348) Total deferred tax assets 1,805 2,193 Deferred tax liabilities: Other (1,128) (1,356) Property and equipment and intangible assets (677) (837) Total deferred tax liabilities (1,805) (2,193) Net deferred tax assets (liabilities) $ — $ —

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Lease, Cost	The weighted-average remaining lease term and discount rate for the years ended December 31, 2022 and December 31, 2021 are as follows: 2022 2021 Weighted average remaining lease term (in years) 8.7 9.5 Weighted average discount rate 5.3% 5.2% Supplemental cash flow information related to operating leases for the years ended December 31, 2022, December 31, 2021 and December 31, 2020 are as follows: (in thousands) 2022 2021 2020 Cash paid for amounts included in the measurement of lease liabilities $ (1,160) $ (646) $ (267) Initial recognition of operating lease right-of-use asset $ 57 $ 419 $ 5,804
Lessee, Operating Lease, Liability, Maturity	Future maturities of operating lease liabilities as of December 31, 2022 are as follows: (in thousands) Operating Lease Payments 2023 $ 982 2024 1,113 2025 1,141 2026 1,169 2027 1,198 Thereafter 4,533 Total lease payments 10,136 Less: imputed interest (2,048) Total $ 8,088

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Summary of Outstanding Warrants and Warrants Outstanding	The warrant activity for 2021 is as follows: Number of warrants Balance at December 31, 2020 1,690 Warrants exercised (1,684) Warrants expired (6) Balance at December 31, 2021 —

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of Option Activity	The following table summarizes the number of stock options outstanding under the Plan for the years ended December 31, 2022. Number of Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding at December 31, 2021 12,074 $ 12.84 7.86 $ 121,141 Granted 3,913 $ 11.14 Exercised/released (77) $ 6.55 Cancelled/forfeited (2,615) $ 14.32 Outstanding at December 31, 2022 13,295 $ 12.09 7.74 $ 21 Options exercisable, December 31, 2022 8,345 $ 11.94 Vested and expected to vest, December 31, 2022 12,884 $ 11.98
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The following weighted average assumptions were used to estimate the fair value of the options granted during the years ended December 31, 2022, 2021 and 2020: 2022 2021 2020 Expected term (in years) 5 years 4 years 3 years Volatility 70 % 66 % 52 % Risk-free interest rate 2.06 % 0.46 % 0.55 % Dividend yield 0.0 % 0.0 % 0.0 %
Schedule of Un-vested Share Activity	The following table summarizes the PA and RSU activity for the year ended December 31, 2022: Number of Shares Weighted-Average Grant Date Fair Value Unvested balance, December 31, 2021 347 $ 13.33 Granted 2,374 $ 11.16 Vested (305) $ 14.17 Forfeited (436) $ 12.21 Unvested balance, December 31, 2022 1,980 $ 10.84
Allocation of Share-Based Payments	Share-based compensation expense for the years ended December 31, 2022, 2021 and 2020 totaled approximately $32.3 million, $31.2 million and $17.5 million, respectively, as shown in the table below. (in thousands) 2022 2021 2020 Research and development $ 3,271 $ 4,442 $ 3,730 Selling, general and administrative 28,438 26,432 13,615 Capitalized under inventories 591 369 109 Share-based compensation expense $ 32,300 $ 31,243 $ 17,454
Share-based Payment Arrangement, Nonvested Award, Cost	As of December 31, 2022, the unrecognized share-based cost, and the estimated weighted-average amortization period, using the straight-line attribution method, was as follows (in thousands, except amortization period): Unrecognized share-based compensation expense Weighted average remaining amortization period (in years) Stock Options $ 10,869 1.12 Restricted Stock Units 10,584 1.52 ESPP 1,327 0.52 Total unrecognized share-based compensation expense $ 22,780 1.30

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	The numerator and denominator used in the calculation of basic and diluted net loss amounts per Common Share are as follows: 2022 2021 2020 Net loss for the year $ (108,180) $ (180,966) $ (102,680) Weighted average number of common shares outstanding 141,915 129,369 118,473 Net loss per common share (expressed in $ per share) $ (0.76) $ (1.40) $ (0.87)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The Company did not include the securities in the following table in the computation of the net loss per common share because the effect would have been anti-dilutive during each period: 2022 2021 2020 Outstanding stock options 13,295 12,074 14,047 Unvested performance awards — 64 — Unvested restricted units 1,980 191 — Warrants — — 1,690 15,275 12,329 15,737

Selected Quarterly Financial _2

Selected Quarterly Financial Information (unaudited) (Tables)	12 Months Ended
	Dec. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
Quarterly Financial Information	The following condensed quarterly financial information is for the years December 31, 2022 and 2021: (in thousands, except per share data) March 31, 2022 June 30, September 30, 2022 December 31, 2022 Total revenue, net $ 21,625 $ 28,191 $ 55,779 $ 28,435 Cost of sales and operating expenses 59,507 64,180 65,278 56,535 Loss from operations (37,882) (35,989) (9,499) (28,100) Net loss (37,630) (35,515) (8,989) (26,046) Basic and diluted loss per common share $ (0.27) $ (0.25) $ (0.06) $ (0.18) March 31, 2021 June 30, September 30, 2021 December 31, 2021 Total revenue $ 914 $ 6,620 $ 14,667 $ 23,404 Operating expenses 51,457 53,754 65,020 56,109 Loss from operations (50,543) (47,134) (50,353) (32,705) Net loss (50,379) (47,010) (50,255) (33,322) Basic and diluted loss per common share $ (0.40) $ (0.37) $ (0.39) $ (0.25)

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Property, Plant and Equipment [Line Items]
Number of operating segments | segment	1
Accounts receivable, net	$ 13,483,000	$ 15,414,000
Allowance for doubtful accounts	0
Cash, cash equivalents	94,172,000	231,900,000	$ 272,350,000	$ 306,019,000
Restricted cash	100,000	300,000
Asset impairment charges	0	0	0
Research and development	44,988,000	51,139,000	50,327,000
Advertising expense	16,300,000	15,400,000	10,000,000
Selling, general and administrative expense	$ 196,400,000	$ 173,500,000	$ 97,300,000
Minimum
Property, Plant and Equipment [Line Items]
Receivables, standard credit terms	30 days
Lease term	12 months
Minimum | Acquired intellectual property and reacquired rights
Property, Plant and Equipment [Line Items]
Acquired intangible assets useful life	10 years
Maximum
Property, Plant and Equipment [Line Items]
Receivables, standard credit terms	45 days
Lease term	128 months
Maximum | Acquired intellectual property and reacquired rights
Property, Plant and Equipment [Line Items]
Acquired intangible assets useful life	20 years
Specialty Pharmacy One | Revenue Benchmark | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration risk percentage	45%
Specialty Pharmacy One | Revenue Benchmark | Customer Concentration Risk | Outside United States
Property, Plant and Equipment [Line Items]
Concentration risk percentage	20%
Specialty Pharmacy One | Accounts Receivable | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration risk percentage	100%
Specialty Pharmacy Two | Revenue Benchmark | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration risk percentage	35%
Specialty Pharmacy Two | Accounts Receivable | Customer Concentration Risk
Property, Plant and Equipment [Line Items]
Concentration risk percentage	100%

Fair Value Measurement - Assets

Fair Value Measurement - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Financial assets:
Total financial assets	$ 389,390	$ 466,078
Level 1
Financial assets:
Total financial assets	94,172	231,900
Level 2
Financial assets:
Total financial assets	$ 295,218	$ 234,178
Derivative, average remaining maturity	7 months	8 months
Level 3
Financial assets:
Total financial assets	$ 0	$ 0
Cash, cash equivalents and restricted cash
Financial assets:
Total financial assets	94,172	231,900
Cash, cash equivalents and restricted cash | Level 1
Financial assets:
Total financial assets	94,172	231,900
Cash, cash equivalents and restricted cash | Level 2
Financial assets:
Total financial assets	0	0
Cash, cash equivalents and restricted cash | Level 3
Financial assets:
Total financial assets	0	0
U.S. agency security
Financial assets:
Total financial assets	4,948
U.S. agency security | Level 1
Financial assets:
Total financial assets	0
U.S. agency security | Level 2
Financial assets:
Total financial assets	4,948
U.S. agency security | Level 3
Financial assets:
Total financial assets	0
Corporate bond
Financial assets:
Total financial assets	104,080	21,820
Corporate bond | Level 1
Financial assets:
Total financial assets	0	0
Corporate bond | Level 2
Financial assets:
Total financial assets	104,080	21,820
Corporate bond | Level 3
Financial assets:
Total financial assets	0	0
Commercial paper
Financial assets:
Total financial assets	125,187	206,724
Commercial paper | Level 1
Financial assets:
Total financial assets	0	0
Commercial paper | Level 2
Financial assets:
Total financial assets	125,187	206,724
Commercial paper | Level 3
Financial assets:
Total financial assets	0	0
Treasury bill
Financial assets:
Total financial assets	12,282	2,494
Treasury bill | Level 1
Financial assets:
Total financial assets	0	0
Treasury bill | Level 2
Financial assets:
Total financial assets	12,282	2,494
Treasury bill | Level 3
Financial assets:
Total financial assets	0	0
Treasury bond
Financial assets:
Total financial assets	42,220
Treasury bond | Level 1
Financial assets:
Total financial assets	0
Treasury bond | Level 2
Financial assets:
Total financial assets	42,220
Treasury bond | Level 3
Financial assets:
Total financial assets	0
Yankee bond
Financial assets:
Total financial assets	6,501
Yankee bond | Level 1
Financial assets:
Total financial assets	0
Yankee bond | Level 2
Financial assets:
Total financial assets	6,501
Yankee bond | Level 3
Financial assets:
Total financial assets	$ 0
Certificates of deposit
Financial assets:
Total financial assets		3,140
Certificates of deposit | Level 1
Financial assets:
Total financial assets		0
Certificates of deposit | Level 2
Financial assets:
Total financial assets		3,140
Certificates of deposit | Level 3
Financial assets:
Total financial assets		$ 0

Cash, Cash Equivalents and Re_3

Cash, Cash Equivalents and Restricted Cash and Short-Term Investments - Narrative (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]
Total cash, cash equivalents, restricted cash and short-term investments	$ 389,400,000	$ 466,078,000
Available-for-sale debt securities	295,500,000	215,000,000
Held-to-maturity securities corporate bond	0	19,228,000
Interest receivable	1,100,000	100,000
Unrealized gains (losses) on available-for-sale securities	$ (300,000)	$ (47,000)	$ (47,000)

Cash, Cash Equivalents and Re_4

Cash, Cash Equivalents and Restricted Cash and Short-Term Investments - Investment (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Marketable Securities [Line Items]
Amortized Cost	$ 389,646,000	$ 446,897,000
Unrealized Gains	0	0
Unrealized Losses	(256,000)	(47,000)
Estimated Fair Value	389,390,000	446,850,000
Held-to-maturity securities corporate bond	0	19,228,000
Total cash, cash equivalents, restricted cash and short-term investments	389,400,000	466,078,000
Cash, cash equivalents and restricted cash
Marketable Securities [Line Items]
Amortized Cost	94,172,000	231,900,000
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	94,172,000	231,900,000
U.S. agency security
Marketable Securities [Line Items]
Amortized Cost	4,951,000
Unrealized Gains	0
Unrealized Losses	(3,000)
Estimated Fair Value	4,948,000
Corporate bond
Marketable Securities [Line Items]
Amortized Cost	104,174,000	2,593,000
Unrealized Gains	0	0
Unrealized Losses	(94,000)	(1,000)
Estimated Fair Value	104,080,000	2,592,000
Commercial paper
Marketable Securities [Line Items]
Amortized Cost	125,255,000	206,764,000
Unrealized Gains	0	0
Unrealized Losses	(68,000)	(40,000)
Estimated Fair Value	125,187,000	206,724,000
Treasury bill
Marketable Securities [Line Items]
Amortized Cost	12,290,000	2,496,000
Unrealized Gains	0	0
Unrealized Losses	(8,000)	(2,000)
Estimated Fair Value	12,282,000	2,494,000
Treasury bond
Marketable Securities [Line Items]
Amortized Cost	42,301,000
Unrealized Gains	0
Unrealized Losses	(81,000)
Estimated Fair Value	42,220,000
Yankee bond
Marketable Securities [Line Items]
Amortized Cost	6,503,000
Unrealized Gains	0
Unrealized Losses	(2,000)
Estimated Fair Value	$ 6,501,000
Certificates of deposit
Marketable Securities [Line Items]
Amortized Cost		3,144,000
Unrealized Gains		0
Unrealized Losses		(4,000)
Estimated Fair Value		$ 3,140,000

Inventories, net (Details)

Inventories, net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Finished goods inventories	$ 3,900
Inventory deposits	5,500	$ 3,900
Raw materials	2,217	2,217
Work in process	21,059	12,566
Finished goods	1,476	4,543
Total inventories, net	$ 24,752	$ 19,326

Prepaid Expenses (Details)

Prepaid Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Receivables [Abstract]
Prepaid assets	$ 5,451	$ 5,316
Prepaid deposits	6,330	4,762
Prepaid insurance	1,799	1,632
Prepaid expenses	$ 13,580	$ 11,710

Property and Equipment, net (De

Property and Equipment, net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 5,105	$ 5,254
Less accumulated depreciation	(1,455)	(836)
Property and equipment, net	3,650	4,418
Depreciation	629	663	$ 82
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	255	393
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 2,978	2,978
Office equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in years)	5 years
Property, plant and equipment, gross	$ 645	645
Furniture
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in years)	7 years
Property, plant and equipment, gross	$ 976	976
Computer equipment
Property, Plant and Equipment [Line Items]
Estimated Useful Life (in years)	3 years
Property, plant and equipment, gross	$ 251	$ 262

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Value	$ 19,568	$ 19,470
Accumulated Amortization	(13,143)	(11,066)
Net Carrying Amount	$ 6,425	$ 8,404
Patents
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	12 years	12 years
Gross Carrying Value	$ 1,569	$ 1,471
Accumulated Amortization	(1,262)	(1,176)
Net Carrying Amount	$ 307	$ 295
Acquired intellectual property and reacquired rights
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	12 years	12 years
Gross Carrying Value	$ 15,126	$ 15,126
Accumulated Amortization	(9,838)	(8,804)
Net Carrying Amount	$ 5,288	$ 6,322
Internal-use software implementation costs
Finite-Lived Intangible Assets [Line Items]
Weighted Average Life (in years)	3 years	3 years
Gross Carrying Value	$ 2,873	$ 2,873
Accumulated Amortization	(2,043)	(1,086)
Net Carrying Amount	$ 830	$ 1,787

Intangible Assets - Narrative (

Intangible Assets - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Upfront license and milestone expense	$ 2.1	$ 2.1	$ 1.3
2023	5.6
2024	5.6
2025	5.6
2026	5.6
2027	$ 5.6

Accounts payable and accrued _3

Accounts payable and accrued liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Employee accruals	$ 20,157	$ 18,500
Commercial accruals	8,620	5,055
Accrued R&D projects	5,350	4,383
Trade payables	3,087	3,879
Other accrued liabilities	2,151	2,316
Income taxes payable	625	814
Accounts payable and accrued liabilities	$ 39,990	$ 34,947

License and Collaboration Agr_2

License and Collaboration Agreements (Details) - USD ($) $ in Thousands

3 Months Ended

12 Months Ended

Aug. 17, 2021

Dec. 31, 2022

Sep. 30, 2022

Jun. 30, 2022

Mar. 31, 2022

Dec. 31, 2021

Sep. 30, 2021

Jun. 30, 2021

Mar. 31, 2021

Dec. 31, 2022

Dec. 31, 2021

Dec. 31, 2020

Sep. 15, 2022

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues

$ 28,435

$ 55,779

$ 28,191

$ 21,625

$ 23,404

$ 14,667

$ 6,620

$ 914

$ 134,030

$ 45,605

$ 50,118

Research and development

44,988

51,139

50,327

Product Sales

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues

103,468

45,488

0

Otuska | License Agreement Terms

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront payments received

50,000

Potential regulatory milestone revenue

$ 50,000

Triggered milestone, payments

$ 30,000

Otuska | License Agreement Terms | Service Revenue

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Revenues

$ 500

$ 0

Otuska | License Agreement Terms | Minimum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Tiered royalty percentages on future sales

1,000%

Otuska | License Agreement Terms | Maximum

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Tiered royalty percentages on future sales

2,000%

Riptide Bioscience, Inc. | License Agreement Terms

Research and Development Arrangement, Contract to Perform for Others [Line Items]

Upfront license fee

$ 6,000

Research and development

$ 4,000

Segment Information and Geogr_3

Segment Information and Geographic Data - Narrative (Details) - Revenue Benchmark - Customer Concentration Risk	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Customer One
Product Information [Line Items]
Concentration risk percentage	45%	56%
Customer Two
Product Information [Line Items]
Concentration risk percentage	35%	43%
Specialty Pharmacy One
Product Information [Line Items]
Concentration risk percentage	45%
Specialty Pharmacy One | Outside United States
Product Information [Line Items]
Concentration risk percentage	20%

Segment Information and Geogr_4

Segment Information and Geographic Data - Revenue by Geographic Location (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	$ 28,435	$ 55,779	$ 28,191	$ 21,625	$ 23,404	$ 14,667	$ 6,620	$ 914	$ 134,030	$ 45,605	$ 50,118
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									102,460	45,488	0
Japan
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									31,481	0	50,000
Other
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues									$ 89	$ 117	$ 118

Segment Information and Geogr_5

Segment Information and Geographic Data - Long-lived Assets by Location (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, net	$ 8,557	$ 9,801
Canada
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, net	322	625
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Long-lived assets, net	$ 8,235	$ 9,176

Income Taxes - Components of In

Income Taxes - Components of Income (Losses) Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Canada	$ (112,359)	$ (180,374)	$ (61,024)
Foreign	6,007	168	(41,750)
Net loss before income taxes	$ (106,352)	$ (180,206)	$ (102,774)

Income Taxes - Provision For In

Income Taxes - Provision For Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current:
Canada	$ 0	$ 0	$ 0
Foreign	1,828	760	(94)
Total Current	1,828	760	(94)
Deferred:
Canada	0	0	0
Foreign	0	0	0
Total deferred	0	0	0
Income tax expense (benefit)	$ 1,828	$ 760	$ (94)

Income Taxes - Effective Income

Income Taxes - Effective Income Tax Rate Reconciliation (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Canada statutory income tax benefit	26.70%	26.80%	26.80%
Effect of tax rates on foreign jurisdictions	0.30%	0%	(2.40%)
Other	(1.10%)	0%	0%
Impact of future rates and tax rate changes	(0.10%)	(0.10%)	6.10%
Foreign tax credit	1.10%	0%	0%
Non-deductible share-based compensation	(8.10%)	(4.50%)	(4.50%)
Change in valuation allowance	(21.50%)	(21.80%)	(26.00%)
Scientific Research and Experimental Development (SRED)	1.10%	0.30%	0.40%
Other	(0.10%)	(1.10%)	(0.30%)
Effective tax rate	(1.70%)	(0.40%)	0.10%
Withholding tax payments	$ 1.2

Income Taxes - Deferred Tax Ass

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carry-forwards	$ 141,020	$ 120,274
Share issue costs	4,209	6,016
Intangible assets	1,400	1,086
SRED (Scientific Research and Experimental Development)	7,462	6,059
Capitalized research and development	1,663	0
Deferred compensation	3,391	3,980
Accruals	2,887	2,653
Other	4,287	3,473
Gross deferred tax assets	166,319	143,541
Valuation allowance	(164,514)	(141,348)
Total deferred tax assets	1,805	2,193
Deferred tax liabilities:
Other	(1,128)	(1,356)
Property and equipment and intangible assets	(677)	(837)
Total deferred tax liabilities	(1,805)	(2,193)
Net deferred tax assets (liabilities)	$ 0	$ 0

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Operating Loss Carryforwards [Line Items]
Increase in valuation allowance	$ (23.2)
Operating loss carryforwards	518.1
Domestic Tax Authority | Canada Investment Tax Credits and British Columbia Scientific Research and Experimental Development
Operating Loss Carryforwards [Line Items]
Tax credit carryforward	5.8
Foreign Tax Authority | United States
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	10.1
Foreign Tax Authority | UNITED KINGDOM
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	0.4
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	$ 0.1

Commitment and Contingencies (D

Commitment and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Long-term Purchase Commitment [Line Items]
Purchase of long-lived assets	$ 292	$ 303	$ 5,668
Lonza
Long-term Purchase Commitment [Line Items]
Non-cancellable future commitments	29,300
Purchase of long-lived assets	$ 5,500

Deferred Compensation and Oth_2

Deferred Compensation and Other Non-current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Other non-current liabilities	$ 12,166	$ 15,950

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Thousands, SFr in Millions		1 Months Ended				12 Months Ended
	Aug. 03, 2022 USD ($)	Feb. 28, 2021 USD ($)	Feb. 28, 2021 CHF (SFr)	Jan. 31, 2021 CHF (SFr)	Mar. 31, 2020 ft² extension_option	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Oct. 31, 2022 ft²	Mar. 12, 2020
Lessee, Lease, Description [Line Items]
Capital expenditure payments		$ 11,800	SFr 10.5
Right-of-use assets, net						$ 4,907	$ 5,383
Operating lease, liability						$ 8,088
Incremental borrowing rate						5.30%	5.20%
Operating lease, cost						$ 1,000	$ 1,000
Payments for capital improvements | SFr				SFr 21
Minimum finance lease liability payments due						85,000
Expected payments prior to commencement of lease						900
Future value of minimum lease payments of leases not yet commenced						100
Victoria, British Columbia
Lessee, Lease, Description [Line Items]
Lease term								18 months
Capital expenditure payments	$ 300
Rockville, Maryland
Lessee, Lease, Description [Line Items]
Area of property (in sqft) | ft²					30,531
Remaining lease term					9 years
Number of extension options | extension_option					2
Lease extension term					5 years
Lease termination renewal option Term					11 years
Lease termination option term					7 years
Right-of-use assets, net						4,900	5,200
Operating lease, liability						$ 8,000	$ 8,600
Proceeds from tenant improvements								$ 2,300
Incremental borrowing rate										5.20%
Edmonton, Alberta
Lessee, Lease, Description [Line Items]
Area of property (in sqft) | ft²									4,375
Remaining lease term									6 years

Leases - Cash Flow and Suppleme

Leases - Cash Flow and Supplemental Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted average remaining lease term (in years)	8 years 8 months 12 days	9 years 6 months
Weighted average discount rate	5.30%	5.20%
Cash paid for amounts included in the measurement of lease liabilities	$ (1,160)	$ (646)	$ (267)
Initial recognition of operating lease right-of-use asset	$ 57	$ 419	$ 5,804

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Lease Liabilities (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Leases [Abstract]
2023	$ 982
2024	1,113
2025	1,141
2026	1,169
2027	1,198
Thereafter	4,533
Total lease payments	10,136
Less: imputed interest	(2,048)
Total	$ 8,088

Shareholders' Equity - Narrativ

Shareholders' Equity - Narrative (Details) - USD ($)				1 Months Ended	12 Months Ended
	Nov. 19, 2021	Jul. 27, 2020	Dec. 28, 2016	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Class of Stock [Line Items]
Common stock, outstanding (in shares)				141,600,000	142,268,000	141,600,000	126,700,000
Common stock, issued (in shares)				141,600,000	142,268,000	141,600,000	126,700,000
Proceeds from exercise of warrants					$ 0	$ 365,000	$ 1,000
Warrants exercised during period (in shares)						1,700,000	500
Warrants
Class of Stock [Line Items]
Warrants exercised during period (in shares)						1,684,000
Number of warrants outstanding (in shares)				0		0	1,690,000
Warrants expired (in shares)						6,000
Common Shares
Class of Stock [Line Items]
Common stock, outstanding (in shares)				141,600,000	142,268,000	141,600,000	126,725,000	111,798,000
November 2021 Open Market Sale Agreement
Class of Stock [Line Items]
Aggregate offering price	$ 250,000,000
Number of shares issued	10,200,000
Weighted average price per share (in usd per share)	$ 19.90
Proceeds from offering				$ 202,400,000
Share issuance costs	$ 5,600,000
Underwriting commissions percentage	3%
Underwriting commissions	$ 5,300,000
Professional fees	$ 300,000
July 2020 Public Offering
Class of Stock [Line Items]
Number of shares issued		13,300,000
Proceeds from offering		$ 200,000,000
Share issuance costs		$ 12,300,000
Underwriting commissions percentage		6%
Underwriting commissions		$ 12,000,000
Professional fees		$ 300,000
Share price (in usd per share)		$ 15
2016 Bought Deal Public Offering
Class of Stock [Line Items]
Number of shares issued			12,800,000
Subscription price per unit (in usd per share)			$ 2.25
Exercise price of warrants (in usd per share)			$ 3	$ 3		$ 3	$ 3	$ 3
Proceeds from exercise of warrants						$ 300,000	$ 2,000	$ 5,500,000
Warrants expired (in shares)						6,000
2016 Bought Deal Public Offering | Warrants
Class of Stock [Line Items]
Proceeds from offering			$ 28,800,000
Share issuance costs			$ 655,000
Warrant exercise period			5 years
Fair value of warrants			$ 7,200,000
Number of warrants outstanding (in shares)					1,600,000
2016 Bought Deal Public Offering | Warrants | 2014 Warrant
Class of Stock [Line Items]
Number of shares called by each warrant (in shares)			0.50
2016 Bought Deal Public Offering | Common Shares
Class of Stock [Line Items]
Number of shares called by each warrant (in shares)			1
Number of shares converted (in shares)						1,300,000

Shareholders' Equity - Warrant

Shareholders' Equity - Warrant Activity (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Class of Warrant or Right [Roll Forward]
Warrants exercised (in shares)	(1,700,000)	(500)
Warrants
Class of Warrant or Right [Roll Forward]
Beginning balance (in shares)	1,690,000
Warrants exercised (in shares)	(1,684,000)
Warrants expired (in shares)	(6,000)
Ending balance (in shares)	0	1,690,000

Share-Based Compensation - Narr

Share-Based Compensation - Narrative (Details) $ / shares in Units, $ in Thousands				1 Months Ended	12 Months Ended
	Aug. 06, 2021 $ / shares shares	Mar. 18, 2021 $ / shares	Oct. 23, 2020 shares	Jun. 30, 2021 shares	Dec. 31, 2022 USD ($) purchase_period $ / shares shares	Dec. 31, 2021 USD ($) purchase_period $ / shares shares	Dec. 31, 2020 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average price (in usd per share) | $ / shares					$ 6.52	$ 7.34	$ 5.58
Fair value of options vested in period | $					$ 49,200	$ 24,900	$ 14,900
Intrinsic value of options exercised | $					$ 900	$ 50,300	$ 13,100
Volatility					70%	66%	52%
Awards granted in period (in shares)					2,374,000
Fair value on grant date (in usd per share) | $ / shares					$ 11.16
Share-based compensation expense | $					$ 32,300	$ 31,243	$ 17,454
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)				2,500,000
Number of shares purchased (in shares)					286,000	37,000
Number of purchase periods | purchase_period					2	4
Purchase period					12 months	24 months
Offering period					12 months
Inducement Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise period					10 years
Award vesting period					3 years
Inducement Stock Option | Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period					12 months
Inducement Stock Option | Tranche Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period					24 months
Unvested performance awards | Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted in period (in shares)			439,000
Fair value on grant date (in usd per share) | $ / shares		$ 13.56
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period					1 year
Performance Share sand Restricted Stock Units (RSUs) | Officer
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted in period (in shares)	619,000
Fair value on grant date (in usd per share) | $ / shares	$ 14.42
Share-based compensation expense | $					$ 11,400
Amended and Restated Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of additional shares authorized (in shares)				23,800,000

Share-Based Compensation - Stoc

Share-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Number of Shares (in thousands)
Beginning balance (in shares)	12,074
Granted (in shares)	3,913
Exercised/released (in shares)	(77)
Cancelled/forfeited (in shares)	(2,615)
Ending balance (in shares)	13,295	12,074
Options exercisable (in shares)	8,345
Vested and expected to vest (in shares)	12,884
Weighted-Average Exercise Price
Beginning balance (in usd per share)	$ 12.09	$ 12.84
Granted (in usd per share)	11,140
Exercised/released (in usd per share)	6,550
Cancelled/forfeited (in usd per share)	14,320
Ending balance (in usd per share)	12.09	$ 12.84
Options exercisable (in usd per share)	11.94
Vested and expected to vest (in usd per share)	$ 11.98
Weighted-Average Remaining Contractual Life (in years)	7 years 8 months 26 days	7 years 10 months 9 days
Aggregate Intrinsic Value	$ 21	$ 121,141

Share-Based Compensation - Weig

Share-Based Compensation - Weighted Average Assumptions (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-Based Payment Arrangement [Abstract]
Expected term (in years)	5 years	4 years	3 years
Volatility	70%	66%	52%
Risk-free interest rate	2.06%	0.46%	0.55%
Dividend yield	$ 0	$ 0	$ 0

Share-Based Compensation - Sche

Share-Based Compensation - Schedule of Un-vested Share Activity (Details) shares in Thousands	12 Months Ended
	Dec. 31, 2022 $ / shares shares
Number of Shares (in thousands)
Unvested balance (in shares) | shares	347
Granted (in shares) | shares	2,374
Vested (in shares) | shares	(305)
Forfeited (in shares) | shares	(436)
Unvested balance (in shares) | shares	1,980
Weighted-Average Grant Date Fair Value
Unvested balance (in usd per share) | $ / shares	$ 13.33
Granted (in usd per share) | $ / shares	11.16
Vested (in usd per share) | $ / shares	14.17
Forfeited (in usd per share) | $ / shares	12.21
Unvested balance (in usd per share) | $ / shares	$ 10.84

Share-Based Compensation - Allo

Share-Based Compensation - Allocated Share-Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 32,300	$ 31,243	$ 17,454
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	3,271	4,442	3,730
Selling, general and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	28,438	26,432	13,615
Capitalized under inventories
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 591	$ 369	$ 109

Share-Based Compensation - Unre

Share-Based Compensation - Unrecognized Share-Based Compensation Expense (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized share-based compensation expense	$ 22,780
Weighted average remaining amortization period (in years)	1 year 3 months 18 days
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized share-based compensation expense	$ 10,869
Weighted average remaining amortization period (in years)	1 year 1 month 13 days
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized share-based compensation expense	$ 10,584
Weighted average remaining amortization period (in years)	1 year 6 months 7 days
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized share-based compensation expense	$ 1,327
Weighted average remaining amortization period (in years)	6 months 7 days

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Net loss	$ (26,046)	$ (8,989)	$ (35,515)	$ (37,630)	$ (33,322)	$ (50,255)	$ (47,010)	$ (50,379)	$ (108,180)	$ (180,966)	$ (102,680)
Weighted average number of common shares outstanding, basic (in shares)									141,915	129,369	118,473
Weighted average number of common shares outstanding, diluted (in shares)									141,915	129,369	118,473
Net loss per common Share, basic (in dollars per share)	$ (0.18)	$ (0.06)	$ (0.25)	$ (0.27)	$ (0.25)	$ (0.39)	$ (0.37)	$ (0.40)	$ (0.76)	$ (1.40)	$ (0.87)
Net loss per common Share, diluted (in dollars per share)	$ (0.18)	$ (0.06)	$ (0.25)	$ (0.27)	$ (0.25)	$ (0.39)	$ (0.37)	$ (0.40)	$ (0.76)	$ (1.40)	$ (0.87)

Net Loss Per Common Share - Ant

Net Loss Per Common Share - Anti-Dilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	15,275,000	12,329,000	15,737,000
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	13,295,000	12,074,000	14,047,000
Unvested performance awards
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	64,000	0
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,980,000	191,000	0
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0	1,690,000

Related-Party Transactions (Det

Related-Party Transactions (Details) $ in Millions	12 Months Ended
	Dec. 31, 2021 USD ($)
ILJIN | Milestone Payment | Affiliated Shareholder
Related Party Transaction [Line Items]
Payments to related party	$ 6

Selected Quarterly Financial _3

Selected Quarterly Financial Information (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]
Total revenue, net	$ 28,435	$ 55,779	$ 28,191	$ 21,625	$ 23,404	$ 14,667	$ 6,620	$ 914	$ 134,030	$ 45,605	$ 50,118
Cost of sales and operating expenses	56,535	65,278	64,180	59,507	56,109	65,020	53,754	51,457
Loss from operations	(28,100)	(9,499)	(35,989)	(37,882)	(32,705)	(50,353)	(47,134)	(50,543)	(111,470)	(180,735)	(104,290)
Net loss	$ (26,046)	$ (8,989)	$ (35,515)	$ (37,630)	$ (33,322)	$ (50,255)	$ (47,010)	$ (50,379)	$ (108,180)	$ (180,966)	$ (102,680)
Basic loss per common share (in dollars per share)	$ (0.18)	$ (0.06)	$ (0.25)	$ (0.27)	$ (0.25)	$ (0.39)	$ (0.37)	$ (0.40)	$ (0.76)	$ (1.40)	$ (0.87)
Diluted loss per common share (in dollars per share)	$ (0.18)	$ (0.06)	$ (0.25)	$ (0.27)	$ (0.25)	$ (0.39)	$ (0.37)	$ (0.40)	$ (0.76)	$ (1.40)	$ (0.87)